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Summary 
 
The World health Organization reports infertility as a disease and a failure of reproductive 
tract to achieve pregnancy after 12 months or more of regular unprotected sexual intercourse. 
Nowadays, infertility has become a common life phenomenon affecting 1 out of 5 couples at 
reproductive age. Idiopathic cause is mostly associated with active immune system which 
may produce high levels of anti-seminal and/or anti-sperm antibodies. Auto-immunization as 
well as iso-immunization has a significant role in up to 30% of reported cases of infertility. 
Semen that is defined as a complex fluid containing sperm, cellular vesicles and other cells 
and components, could immunize the female genital tract. 
This thesis is related to female immune infertility, in particular to female iso-immunization. 
The better understanding of this pathophysiological event consists of (1) the determination of 
antibody isotype playing a significant role in this disease, then (2) the characterization and 
identification of semen antibody-binding proteins, seminal and/or sperm, (3) the proposal of 
potential diagnostic markers to adapt specific therapy and, in addition, the design of 
miniaturized diagnostic tool based on the selected markers, (4) the suggestion of potential 
immuno-intervention.  
Based on the distribution of seminal/sperm-specific antibody isotypes, we suggest that 
immunoglobulins E, M, A1,2, G3 are not involved in the primary pathophysiological female 
sensitization. IgG4 appears to be the major subclass interacting with sperm proteins. On a 
contrary, IgG1 seems to be the one mainly involved in the reactivity towards seminal proteins. 
We have also extended the existing group of IgG-binding sperm proteins, among which heat 
shock protein 70 1A/1B, heat shock cognate protein 71 kDa and alpha-enolase have been 
shown, for the first time, to be related to female iso-immunization. We have put the emphasis 
on the role of seminal proteins in iso-immunization and not only in the IgE-mediated semen 
hypersensitivity as known so far. In particular, prostate-specific antigen, prostatic acid 
phosphatase and zinc finger protein 778 have been determined as immunodominant among 
IgG-binding seminal proteins.  
The determination of female serum seminal/sperm-specific IgG subclasses could make the 
patient diagnoses more comprehensive. Anti-seminal/sperm IgG1,4 might be of interest for 
immunotherapy. Furthermore, the herein described proteins could be useful biomarkers of 
such pathology. The miniaturized chip could be a lateral flow immunoassay-based device 
acting on the immunochemical detection of specific antibodies. The intended immuno-
intervention could consist of the effect of intravenous immunoglobulins. 
Résumé 
 
L‟Organisation Mondiale de la Santé définit l‟infertilité comme une maladie et un échec de 
l‟appareil reproducteur à parvenir à une grossesse après 1β mois ou plus de rapports sexuels 
réguliers non protégés. De nos jours, l‟infertilité est devenue un phénomène commun 
affectant 1 couple en âge de procréer sur 5. Une origine idiopathique est le plus souvent  
associée à un système immunitaire actif qui pourrait produire des niveaux élevés d‟anticorps 
anti-liquide séminal ou anti-sperme. L‟auto-immunisation, aussi bien que l‟iso-immunisation, 
joue un rôle significatif dans jusqu‟à γ0% des cas signalés. Le liquide séminal, qui est défini 
comme un fluide complexe contenant le sperme, les vésicules cellulaires et autres cellules et 
composantes, pourraient immuniser l‟appareil génital féminin.  
Cette thèse est liée à l‟infertilité féminine immune, en particulier à l‟iso-immunisation 
féminine. Une meilleure compréhension de cette manifestation physiopathologique consiste 
en (1) la détermination des isotypes d‟anticorps jouant un rôle significatif dans cette maladie, 
puis en (β) la caractérisation et l‟identification  des antigènes de liquide séminal ou de sperme 
reconnus par ces anticorps, (3) la proposition de marqueurs diagnostiques potentiels afin 
d‟adapter des thérapies spécifiques, et, en outre, la conception d‟un outil de diagnostic 
miniaturisé basé sur les marqueurs sélectionnés, (4) la suggestion d‟une éventuelle immuno-
intervention.  
En se fondant sur la distribution des isotypes d‟anticorps spécifiques au liquide 
séminal/sperme, nous suggérons que les immunoglobulines E, M, A1,2, et G3 ne sont pas 
impliquées dans la sensibilisation physiopathologique chez les femmes. Les IgG4, semblent 
constituer la sous classe majeure interagissant avec les protéines de sperme. A l‟inverse, les 
IgG1 semblent être principalement impliquées dans la réactivité vis-à-vis des protéines 
séminales. Nous avons également élargi le groupe déjà existant d‟IgGs liés aux protéines de 
sperme à d‟autres protéines, parmi lesquelles la protéine de choc thermique 70 1A/1B, la 
protéine apparentée aux protéines de choc thermique 71kDa et l‟alpha-énolase ont été 
reconnues, pour la première fois, être liés à l‟iso-immunisation féminine. Nous avons mis en 
évidence le rôle des protéines séminales dans l‟iso-immunisation et pas seulement dans 
l‟hypersensibilité au sperme par l‟intermédiaire d‟IgE. En particulier, l‟antigène spécifique de 
la prostate, la phosphatase acide prostatique et la protéine à doigt de zinc 778 ont été décrites 
comme immuno-dominants parmi les protéines séminales reconnues par des IgGs liés aux 
protéines de sperme.  
  
La détermination des sous classes d‟IgG de sérum féminin, spécifiques au liquide 
séminal/sperme, pourrait rendre le diagnostic des patients plus complet. Les IgG1 et IgG4 anti-
liquide séminal/sperme pourraient présenter un intérêt pour l‟immunothérapie. Par ailleurs, les 
protéines décrites, dans notre étude, pourraient se révéler être des bio marqueurs utiles pour 
de telles pathologies. Le dispositif miniaturisé pourrait être de type LFIA (Lateral Flow 
Immuno Assay), se basant sur la détection immuno-chimique d‟anticorps spécifiques. 
L‟immuno-intervention envisagée pourrait reposer sur l‟effet d‟immunoglobulines 
intraveineuses.  
  
 
 
Aims of the thesis 
 
1. Determine the distribution of serum semen-specific antibodies, which 
immunoglobulin classes, in particular which subclasses, play a significant role in 
female immune infertility within the patient group selected 
a. Quantify the anti-seminal/sperm antibodies in the sera of infertile female 
patients 
b. Compare the observed distribution of anti-seminal/sperm antibodies in the sera 
of fertile healthy women 
 
2. Propose a method for the characterization of semen antigens associated with antibody 
formation involved in the pathophysiological iso-immunization 
a. Characterize the immunodominant seminal and sperm patterns in order to keep 
as much as possible detectable epitopes of potential seminal/sperm antigens 
b. Identify the immunodominant antigen repertoire detected by the sera of female 
patients diagnosed with the selected fertility disorder 
 
3. Verify suggested protocols 
a. Verify the results in order to generalize the knowledge of antigens detected by 
the sera of infertile women 
b. Detect both seminal and sperm antigenic structures by the sera of fertile 
women in order to confirm the relevance of previous results 
 
4. Propose the potential use of obtained results 
a. Suggest potential diagnostic markers to adapt specific therapeutic treatments 
b. Based on the selected markers, design a miniaturized diagnostic tool that could 
refine, simplify and hasten the diagnosis in order to make patient profiling 
more precise and to improve the diagnosis that may differentiate between 
seminal- and sperm-sensitivity 
c. Propose a therapeutic immuno-intervention 
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1 INTRODUCTION 
 
The World Health Organization (WHO) defines infertility as a disease of the reproductive 
tract characterized by the failure to achieve pregnancy after 12 months or more of regular 
unprotected sexual intercourse. Infertility has increased over the last 30 years, WHO 
announced that the number of infertile couples has been increasing worldwide, up to 2 million 
per year. In 2003, infertility was reported as the most prevalent chronic health disorder 
concerning couples regardless of age. The causes of infertility are diagnosed at side of a man 
as well as a woman, about 40% of the time per each. The rest, about 20% of the time, the 
fertility problems are equally shared by both of them. An undeniable fact is the reproductive 
age, to which infertility is related. The maximal female fertility is reached at the age of 19 to 
25. On a contrary, male fertility potential is not limited. However, the quality of semen 
decreases. Besides, the issues of conceiving are associated with worsened state of the 
environment and stress as well. The background of infertility is based on congenital, 
hormonal, morphological and immunological disorders. It may also be related to other 
diseases. Nevertheless, a specific, 100% sure, cause has never been diagnosed.  
In 15% of all cases, the idiopathic cause is suggested, further linked to immune infertility. The 
failure of natural tolerance leads to local/systematic immune system response resulting in the 
immune rejection of male sperm. Female immune infertility has become a serious health issue 
at the level of reproductive immunology.  
The presented thesis is focused on female immune infertility. The better understanding of 
this pathophysiological event consists of the characterization and identification of semen 
proteins, seminal and/or sperm, which are involved in the iso-immunization avoiding the 
fertilization. At the same level, the experimental part reveals which antibody isotype, even 
which antibody subclass plays a significant role in this disease. Despite the fact that female 
immune infertility is not, nowadays, considered as an auto-immune disease, the effect of 
intravenous immunoglobulins could be of therapeutic significance. 
The results of this doctoral thesis contribute to a detailed patient diagnosis and an 
improved therapy. The data shown suggests the potential diagnostic markers that might be of 
value for the following treatment and might lead the design of a diagnostic tool that could 
refine, simplify and hasten the diagnosis to differentiate between seminal- and sperm-
sensitivity. 
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2 MALE FACTOR IN REPRODUCTION 
 
Human semen is produced as a concentrated suspension of spermatozoa stored in the paired 
epididymides. During ejaculation it is mixed with, and diluted by, fluid secretions from the 
accessory sex organs. It is present as a fluid conglomerate emitted in several boluses. Semen 
has two major quantifiable attributes: (1) the total number of spermatozoa reflecting sperm 
production by the testes and the potency of the post-testicular duct system, (2) the total fluid 
volume reflecting the secretory activity of the glands. Semen reflects a heterogeneous cell 
suspension that differs among individuals in protein content, sperm number, pH, volume etc. 
These factors defined by the World Health Organization (WHO) are crucial when judging 
semen quality. Semen quality (Tab. 1, 2) is taken into account to measure male fertility in 
clinical andrology, male fertility, reproductive toxicology, epidemiology and pregnancy risk 
assessments (WHO, 2010). The quality of semen is verified by the presence of several 
components. For instance, the abundance of proteolytic fragments, decreased seminal level of 
albumin, poor testicular contribution characterize the oligozoospermic ejaculates. Seminal 
glycoprotein deficiency, the increased level of acid phosphatase and increased prostatic 
secretory activity are associated with asthenozoospermia (Autiero et al., 1991). Since specific 
substances can be assigned to specific reproductive compartments, chemical substances serve 
as diagnostic markers. Neutral -glucosidase, carnitine, glycerolphosphocholine represent the 
indicators of epididymal functions. Prostate function is evaluated according to the levels of 
fructose, prostaglandins, citrate, zinc and prostatic acid phosphatase (Rowe et al., 1993). 
Semen also contains several immunoregulatory factors as well as immunogenic agents that 
represent the possible targets of activated inflammatory cytokines, leukocytes and 
complement cascade in any part of the female genital tract (Chung et al., 1994;  
Sharkey et al., 2007; Rodriguez-Martinez et al., 2011). One of the most common devices to 
evaluate spermiogram is the Makler counting chamber. It is composed of a metallic base unit, 
semi-circular ring, cover glass with surface graticule (Fig. 1, Makler, 1980). 
The inability to achieve penile erection or to maintain an erection until ejaculation, caused 
by the congenital, neurological and metabolic disorders or abnormalities, is known as erectile 
dysfunction (impotentia coeundi). In addition, if spermatogenesis is disrupted, it results in the 
inability to procreate (impotentia generandi) (Ulcova-Gallova, 2006).  
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Fig. 1 Makler counting chamber, metallic base tool to evaluate sperm amount. (Makler, 1980) 
 
 
Tab. 1 Semen characteristics (WHO, 2010) 
 
Semen type Description 
aspermia no semen/no mature sperm in semen 
no/retrograde ejaculation 
asthenozoospermia percentage of progressively motile sperm below the lower reference limit 
asthenoteratozoospermia percentages of both progressively motile and morphologically normal 
sperm below the lower reference limit 
azoospermia no sperm in the ejaculate, activity of seminal enzymes retarded 
cryptozoospermia 
less than 1 million of sperm in the ejaculate or none are seen on an 
initial evaluation, but only after centrifugation and concentration of the 
sample 
haemospermia presence of erythrocytes in the ejaculate 
leukospermia  presence of leukocytes in the ejaculate  
necrozoospermia low percentage of live sperm, high percentage of immotile/dead sperm in the ejaculate 
normozoospermia total number of sperm and percentages of progressively motile and 
morphologically normal sperm equal to/above the lower reference limit 
oligoasthenozoospermia total number of sperm and percentage of progressively motile sperm less than 20 million 
oligoasthenoteratozoospermia total number of sperm and percentages of both progressively motile and 
morphologically normal sperm below the lower reference limit 
oligoteratozoospermia total number of sperm and percentage of morphologically normal sperm below the lower reference limit 
oligozoospermia total number of sperm below the lower reference limit 
teratozoospermia percentage of morphologically normal sperm below the lower reference limit 
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Tab. 2 Reference limits for semen characteristics (Cooper et al., 2010) 
 
Semen characteristics Reference limit 
volume >1.5 ml 
pH 7.1 – 7.8 
sperm concentration > 20 mil/ml 
total sperm amount > 40 mil 
vitality > 75% 
motility > 50% motile 
morphology > 50% normal morphology 
agglutination < 2 (scale 0 - 3) 
viscosity < 3 (scale 0 - 4) 
liquefaction within 30 min 
leukocytes < 1 mil/ml 
 
 
2.1 Seminal fluid 
 
Seminal fluid (SF), also cited as seminal plasma, represents a part of the semen containing a 
range of organic/inorganic substances (e.g. neutral α-glucosidase, hyaluronidase, carnitine, 
glycerolphosphocholin, fructose, prostaglandins, citrate, zinc, selenium) that are necessary for 
the physiological metabolism of sperm. The seminal complex mixture of secretions originates 
in the testis, epididymis and accessory glands including the prostate, seminal vesicles and 
Cowper‟s gland. It also acts as a nutritive, transport and buffering medium of pH 7.35 - 7.5 
that defines the main SF functions: sperm protection from the acidic environment of the 
vagina, metabolic support and competence, liquefaction and clot formation. SF composition is 
similar to blood plasma. However, it differs in saccharide content (Kumar et al., 2009; 
Rodriguez-Martinez et al., 2011; Brazdova et al., 2012a).  
Semen liquefaction is caused by the fibrinolytic activity of some proteinases and 
peptidases present in prostatic SF. The key role of seminal enzymes (kallikrein-like protease 3, 
prostate-specific antigen) consists of a clot digestion formed immediately after ejaculation. It 
is said that SF containes hundreds of proteins of molecular or catalytic activity including 
additional proteins classified as their regulators (Yousef and Diamandis, 2001; Pilch and 
Mann, 2006). 
In general, seminal proteins can be divided into three different groups. The first group 
contains the extracellular and intracellular proteins supporting basic SF function. The second 
group, originating in proteasomes and membrane-enclosed structures, is mainly involved in 
oocyte-sperm fusion. The third group is known as the potential biomarkers of testis/prostate 
cancer and male infertility as they represent the abraded epithelial cells from tissue surface 
(Pilch and Mann, 2006). 
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SF is in routine examined to evaluate pathological spermiogram and to monitor the 
progression of either testis or prostate cancer. In particular, prostate cancer is diagnosed by 
the seminal level of prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), 
prostate stem-cell antigen or glutamate carboxypeptidase II that is a prostate-specific 
membrane antigen (Jones, 1991; Ostrowski and Kuciel, 1994; Cao et al., 2003). Prostate 
cancer can be diagnosed by the serum PSA level. The serum concentration of 4 ng/ml means a 
20-30% risk of prostate cancer. The risk increases approximately to 60% with a PSA level 
higher than 10 ng/ml (Fung et al., 2004). An early elevated level of serum zinc alpha-2-
glycoproteins (ZAG), originally secreted by the prostate, indicates tumor growth as well. PSA, 
PAP and prostate-specific protein-94 (PSP-94) belong to the prostate secretion that accounts 
for about 30% of the total SF volume. This SF fraction is in direct contact with sperm and is 
the first to confront the cervical tissues. PSA ( -seminoprotein, seminin, kallikrein-3, P30 
antigen, semenogelase) is a 33 kDa member of the glandular kallikrein subfamily of serine 
proteases. In particular, it is a member of the kallikrein subgroup of the (chymo)-trypsin 
serine protease family. It differs from the prototype member of this subgroup, tissue kallikrein, 
by possessing specificity more similar to that of chymotrypsin than trypsin. PSA is known as 
a zinc-binder and the most common protease in human semen. It is mainly released in 
proteasomes. It hydrolyzes semenogelin-1, thus leading to the liquefaction of the seminal 
coagulum. Its activity is strongly inhibited by zinc ions. This inhibition is relieved by 
exposure to semenogelins, which are avid zinc binders (Espana et al., 1991; Utleg et al., 2003; 
Pilch and Mann, 2006). PAP belongs to histidine acid phosphatase family, is stored in 
lysosomes and has an acid pH optimum below 7.0. It is a non-specific tyrosine phosphatase 
that dephosphorylates macromolecules and inactivates lysophosphatidic acid in SF. Its 
isoform 2 acts as a tumor suppressor of prostate cancer through the deactivation of mitogen-
activated protein kinases. Decreased PAP level exhibits poor liquefaction (Autiero et al., 1991; 
Tanaka et al., 2004). 
It contains the membrane-enveloped secretory vesicles. The fructose level is a marker of 
seminal vesicle function. High concentration of fructose is essential for sperm survival in the 
female reproductive tract. Fructose and other sugars are a source of energy for mitochondria-
rich sperm. A decreased fructose level means a lower intensity of fructose oxidation. It leads 
to a lactate accumulation, which results in reduced sperm motility (Anderson et al., 2004). SF 
is rich in proteins secreted by seminal vesicles. Semenogelin I and II, fibronectin and 
fibronectin-related derivates belong to the gel-forming proteins. They are active after the 
cleavage by kallikrein-like protease and then have a role in entrapping sperm into a viscous 
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gel immediately after ejaculation. They are also involved in sperm capacitation and sperm-
oocyte interaction. Another SF element is lactoferrin, thanks to which SF may have an 
antimicrobial activity. SF content also involves albumin, serum and testis derived, that is a 
predominant protein participating in cholesterol removal from the sperm membrane during 
capacitation. The decreased seminal level of albumin and the increased seminal level of 
cholesterol are found in oligozoospermic men (Lilja et al., 1987; Autiero et al., 1991; 
Kosanovic and Jankovic, 2010). 
Seminal components that bind to the acrosomal sperm head region protect sperm and are 
then carried together with it into the higher female genital tract. SF plays an important role 
in moving the sperm into the female reproductive tract due to its high content of transforming 
growth factor beta (TGFȕ) and prostaglandin E (PGE), both of which inhibit the function of 
natural killer (NK) cells and neutrophils that are recruited into the superficial epithelial layers 
of the cervical tissues. SF is rich in PGE of 19-hydroxy form that promotes an expression of 
chemotactic interleukin 8 (IL-8). TGFȕ is synthesized in the prostate and is  
testosterone-dependent. This glycoprotein belongs to cell-secreted molecules and occurs in  
75% in the latent form in SF. It is further activated in the female reproductive tract by either 
the enzymes of male/female origin, acidic vaginal pH or through conformational change after 
an interaction with epithelial cells. The remaining proportion of TGFȕ, β5%, exists in an 
active form (Denison et al., 1999; Robertson et al., 2002). TGFȕ acting may result in the 
immune tolerance of seminal antigens, for which TGFȕI is, most likely, responsible. It is a 
cytokine of TGFȕ family. A divergent member of this family is growth/differentiation factor 
15 (GDF 15), which is highly abundant in SF. Surprisingly, its level is not related to semen 
quality but its expression serves as a cancer marker, often in combination with PSA. However, 
GDF 15 has antitumorigenic activity. In contrast, the high level of GDF 15 in female serum 
corresponds to spontaneous abortion as it is expressed in placenta as well. It has been 
suggested that thanks to the presence of seminal antigens on a conceptus, TGFȕ facilitates the 
female immune tolerance to a fetus (Robertson, 2005; Soucek et al., 2010). 
SF includes a repertoire of signaling molecules interacting with epithelium in the female 
reproductive tract. SF may modulate the chemotactic and phagocytic response of the female 
reproductive tract. Phagocytes serve to filter out the morphologically abnormal sperm. Sperm 
selection is based on morphological or antigenic structures. Mainly, the immune modulating 
properties are mediated by the prostaglandins of the E series, complement inhibitors, 
cytokines and proteins capable to bind IgG antibodies (Tomlinson et al., 1992;  
Kelly and Critchley, 1997). Local reactions may lead to an inflammation (Robertson, 2005). 
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However, SF has a built-in mechanism preventing an immunological sensitization of the 
female against sperm as well as seminal structures. This protective system exists due to the 
presence of immune inhibitors originating in the male sex accessory glands (Prakash, 1981). 
SF has been suggested to be the modulator of sperm-induced inflammation that leads to sperm 
elimination from the female genital tract (Troedsson et al., 2005).  
SF elicits endometrial changes by inducing pro-inflammatory cytokines and 
cyclooxygenase-2. Their presence leads to macrophage and dendritic cell recruitment into the 
female reproductive tract. Seminal components activate the income of neutrophils into the 
endometrial stroma (Robertson, 2005; Bronson, 2011; Morrell et al., 2012). However, it has 
been proved that the influx of neutrophils is higher and faster when the washed sperm 
inseminated (Rozeboom et al., 1999). This fact proves the protective and signaling activity of 
SF. The immuno-suppressive activity prevents the iso-immunization of the female 
reproductive tract and suppresses the cell-mediated cytotoxicity (Lord et al., 1977). Seminal 
prostaglandin D2 is known for its immuno-suppressive effect, by which the anti-sperm 
antibody formation is avoided in the female genital tract. The immuno-modulating properties 
are mediated by prostaglandin E, complement inhibitors, cytokines and proteins capable of 
binding the Fc region of IgG. These IgG-binding proteins are Fc  receptor-like proteins. In 
general, seminal antibody-binding proteins contribute to sperm protection against immune-
mediated damage by enabling successful sperm passage in the female reproductive tract and 
by blocking an interaction with immune effectors. For instance, prolactin-inducible protein 
(PIP), which is a secretory glycoprotein located in seminal vesicles, binds to immunoglobulin 
G via its Fc fragment, it may therefore be involved in immune regulation by trapping anti-
sperm antibodies (ASA) and neutralizing them (Chiu and Chamley, 2002; Chiu and Chamley, 
2003). 
SF has been considered to be linked to the IgE-mediated rare reaction to semen  
(Weidinger et al., 2006). This rare phenomenon was firstly reported by James (1945). Human 
seminal plasma allergy (HSPA) or the so-called hypersensitivity to semen is defined by 
localized and/or systemic symptoms after exposure to seminal fluid. The symptoms occur 
immediately after contact with semen or even within several hours after intercourse. The local 
symptoms include vulvar/vaginal itching, burning, redness and swelling. Local reaction can 
appear on any semen contact site. Local symptoms can be misdiagnosed as chronic vulvo-
vaginitis caused by bacteria, yeasts, viruses and other parasites. Systemic features include 
generalized urticaria, angioedema (face, tongue, lips, throat), dyspnea, wheezing, cough, chest 
tightness, rhinorrhea, nausea, vomiting, diarrhea. Generalized malaise may result in an 
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anaphylactic shock, which is a life-threatening reaction. The symptoms can manifest after the 
first time intercourse in up to 50% of cases. Response mediated by IgE antibodies is then the 
most common mechanism. It has been suggested (Basagana et al., 2008) that female patients 
experiencing any allergic symptoms after/during the first time intercourse might be sensitive 
to other antigens/allergens that cross-react with SF. Basagana et al. (2008) has already proved 
the IgE cross-reactivity among proteins from dog epithelium and PSA. Patients diagnosed 
with HSPA have difficulties conceiving but infertility has not been demonstrated, so far (Shah 
and Panjabi, 2004; Weidinger et al., 2006; Bernstein, 2011).  
 
 
2.2 Spermatozoa 
 
Mature male gamete is commonly known and cited as sperm but specifically called as 
spermatozoa. It was firstly described in 1677 by Anthony van Leeuwenhoek. Sperm is a male 
reproductive cell of approximately 55-65 µm, containing genetic information and 
participating in the fertilization of an ovum (150-300 µm). Sperm consists of a head, middle 
section (mid-piece) and tail (Fig. 2). It is characterized by a minimum of cytoplasm. The head 
contains a nucleus, its shape is flat and oval in order to attach and easily penetrate an oocyte. 
An anterior peak of sperm head carries a cap-like structure called acrosome. It is designed, 
thanks to its hydrolytic enzymes, to help the sperm to penetrate the oocyte. The middle 
section consists of mitochondrial spiral, outer dense fibers and core microtubular structures. 
The mitochondrial formation contains the enzymes of oxidative phosphorylation. The mid-
piece is, therefore, composed of substances that propel the tail. The tail enables the sperm to 
be motile by rotating in a circular motion, not from side to side like a whip (Collins discovery 
encyclopedia, 2005). The speed of sperm in ejaculate ranges from 10 to 60 µm/s. Its 
movement is based on the enzymatic and microtubule components, and is calcium and 
magnesium dependent. The tail is able to move ten times per second. Twenty thousand 
movements are estimated to be needed to reach the oocyte. In vitro, the speed is positively 
influenced by methylxanthins, lower temperature, and negatively by proteolytic enzymes, 
hydrogen peroxide and human saliva as it contains amylase and lysozyme enzymes  
(Ulcova-Gallova, 2006).  
Normal sperm is characterized by an oval head with a long tail. Abnormal sperm has the 
defects of any body part (Fig. 3). Defects occurring on the head cause different shapes: large 
(giant), small (micro), elongated, irregular, amorphous, and then involve the acrosome 
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deficiency and the so-called bicephalic head. The defective mid-piece is asymmetric, bent, 
thin, thick, irregular or with cytoplasmic droplets. The defective tail is coiled, shortened, 
hairpined, broken, duplicated or with terminal droplets. Any defects may impair the ability of 
the sperm to reach and fertilize the oocyte. In general, sperm morphological abnormalities are 
related to congenital background, varicocele, high fever, infection or drug use (Gilbert, 2000). 
 
 
 
Fig. 2 Sperm description. L: length, W: width. Based on Warwick (2006), du Plessis et al. (2011). 
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Fig. 3 Examples of sperm morphological abnormalities, head, mid-piece, tail defects. (MFMER, 2013) 
 
 
2.2.1 Spermatogenesis 
 
Spermatogenesis (Fig. 4) is a complex process creating functional sperm, starting at puberty 
and ending with death. It occurs in the testis, progresses to the epididymis and takes 
approximately 64 days for completion. Effective maturation is conditioned by temperature, 
2 °C lower than body temperature. This explains its location in external genitals. Sperm cells 
are then stored in the epididymides. The entire process is regulated by hormones (follicle 
stimulating hormone, luteinizing hormone, testosterone). It consists of three major steps:  
(1) the multiplication of spermatogonia by mitosis, (2) meiosis to reduce the chromosome 
number from diploid to haploid, (3) the successful transformation of the round spermatid into 
the so-called spermatozoa. The spermatogonial population is created from the germ cells in 
the testis. The population then fuses with the Sertoli cells by creating seminiferous cords. 
After multiplication, several types of spermatogonia are distinguished: type A and B. The 
subsequent meiosis reduces the chromosome number from a diploid to a haploid form of type 
B spermatogonia. Type A diploid spermatogonium divides into two diploid cells called 
primary spermatocytes. The newly developed cells migrate into seminiferous tubules to 
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undergo the meiosis by creating the secondary spermatocytes. The secondary spermatocytes 
are haploid. The next step reflects the forming of rounded spermatids. The differentiated 
spermatids mature in the epididymis into functional spermatozoa. There is an evidence of 
post-translational modifications that are considered to be essential for efficient spermatozoa. 
Some of them can activate capacitation directly in the epididymis or post-ejaculatory in the 
female reproductive tract. The cascade of modifications includes phosphorylation, 
glycosylation, proteolytic cleavage and methylation. A healthy man is usually able to produce 
up to 100 million of sperm/day. However, the concentration of 20 million/ml reflects, 
nowadays, the mean amount (Ulcova-Gallova, 2006; Warwick, 2006; Vacek, 2006;  
du Plessis et al., 2011). 
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Fig. 4 Schematic view of complex spermatogenesis and following processes - maturation, capacitation, fertilization. Based on du Plessis et al. (2011). 
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2.2.2 Capacitation 
 
Sperm capacitation was independently discovered by Austin (1951) and Chang (1951). 
Capacitation is defined as the process, by which the sperm becomes able to undergo an 
acrosome reaction in the uterus, then to penetrate and fertilize the oocyte.  
The main purpose of sperm capacitation (Fig. 5) consists of hyperactivation in order to 
reach the oocyte, particularly in the remodeling of sperm membrane with regards to the fusion 
with the oocyte (Sutovsky, 2011). Capacitation involves a sperm surface remodeling, protein 
phosphorylation, hyperpolarization, an increased membrane fluidity, internal Ca2+ 
concentration and pH. A number of different seminal factors have been shown to act as the 
initial factors of capacitation: fertilization promoting peptide, adenosine, calcitonin, heparin 
binding proteins and angiotensin II. Other participating messengers are derived from sperm-
oocyte interaction. Other factors originate in the female reproductive tract such as leukocytes, 
progesterone, fertilization promoting peptide, cholesterol, sialic acid binding proteins, 
capacitation-associated tyrosine-phosphorylated proteins, heparin binding proteins and atrial 
natriuretic peptide (Storey, 1995; Kumar et al., 2008).  
Capacitation requires a period of sperm incubation in the female tract, approximately  
1 hour. It involves an increased metabolic activity, higher motility and the removal of the 
decapacitation factors from the sperm followed by the destabilization of the acrosomal sperm 
head membrane. This change involves the removal of steroids and seminal glycoproteins from 
sperm membrane. It allows greater binding between sperm and oocyte. Thanks to Ca2+ 
permeability, the binding is strengthened. An influx of Ca2+ results in sperm hyperactivation, 
which induces the higher cAMP level. Ca2+ and HCO3- play a critical role in the regulation of 
sperm function, most likely by acting as the enzyme effectors involved in signal transduction 
(Yanagimachi, 1994). Furthermore, the sperm adenylyl cyclase is significantly stimulated by 
HCO3-. The bicarbonate anion increases an intracellular pH and has been suggested to act as 
an anion antiport with respect to Ca2+ (Okamura et al., 1985). 
The major sperm sterol is cholesterol, among others e.g. desmosterol, desmosterol sulphate, 
cholesterol sulphate, cholesterol esters, cholestadienol. Additional cholesterol may be 
obtained from seminal plasma. Cholesterol moves from the sperm membrane to the acceptors 
and phospholipids into the sperm membrane. The ratio of cholesterol/phospholipids in a 
freshly ejaculated sperm is about 0.8. Albumin acts as a sink for the removal of cholesterol 
from the sperm plasma membrane. The loss is initially linear and leads to the exposure of a 
mannose receptor. Zona pellucida (ZP), an oocyte membrane composed of proteins (70%) and 
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saccharides (30%), contains mannose that interferes with sperm receptors. Cholesterol also 
inhibits the responsiveness and Ca2+/H+ exchange in the ionophores. It has been suggested 
that the increased cholesterol level has a role in male unexplained infertility since the 
concentration is about twice as high as in the fertile subjects. Cholesterol efflux corresponds 
to an increased level of tyrosine as well as proline protein phosphorylation. The sperm 
cholesterol level varies among individuals (Mitra and Shivaji, 2005; Jha et al., 2006).  
Sperm protein tyrosine phosphorylation (PTP) has been considered to be the key signaling 
pathway. It is thought that it acts as a signal to alter mitochondrial function. Sperm PTP is 
dependent on the presence of calcium and bicarbonate ions. It is supported by ATP from 
glycolysis and is regulated through a protein kinase A (PKA) pathway. However, glucose is 
thought to inhibit PTP, which could be up-regulated by free radicals, most likely by 
superoxide anion. Moreover, the superoxide anion generation is also related to sperm lipid 
peroxidation, hyperactivation and viability (de Lamirande and Gagnon, 1993,  
Visconti et al., 1998).  
Capacitation also involves the membrane hyperpolarization caused by K+ permeability. It 
has been speculated whether K+ throughput independently allows the recruitment of Ca2+. 
Subsequently, the membrane potential is increased in tens of mV (Zeng et al., 1995;  
Visconti et al., 1998). 
An essential capacitation factor is a fertilization promoting peptide (FPP), a tripeptide  
(Glu-Glu-Pro) synthesized in the prostatic glands. FPP is present in SF and comes into contact 
with sperm after ejaculation. It becomes less active in the female genital tract due to vaginal 
acidic pH. It has a synergic stimulatory effect with adenosine that increases adenylyl cyclase 
activity in the sperm. Another seminal protein, semenogelin, appears to block sperm 
capacitation (Fraser and Osiguwa, 2004). 
Sperm proteasome, located on the inner acrosomal membrane, is also involved  
in capacitation thanks to its proteolytic activity. It assists in protein removal during membrane 
remodeling, acrosome exocytosis by the degradation of membrane proteins in order to release 
the acrosomal matrix and to create the so-called acrosomal ghost. The sperm is then prepared 
to penetrate and fertilize the metaphase II-arrested oocyte (Sutovsky et al., 2004;  
Zimmerman and Sutovsky, 2009). 
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Fig. 5 Theoretical trans-membrane and intracellular signaling of sperm capacitation. PKA: protein 
kinase A, +/-: stimulating/inhibiting pathways,  consequence,  reaction, ion 
exchange. Based on de Lamirande and Gagnon (1993); Zeng et al. (1995); Visconti et al. 
(1998). 
 
 
2.2.3 Acrosome reaction 
 
Capacitated sperm becomes hyperactivated with regards to motility. Then, it is able to 
recognize the oocyte. The sperm membrane is destabilized after capacitation. It can be 
attached to ZP and undergo an acrosome reaction (AR). Gradual steps are mediated by an 
osmo-sensitive signal transducing mechanism. An oocyte-sperm fusion is coordinated by the 
carbohydrate-protein interaction. The carbohydrate-binding site on the sperm interacts with 
the oligosaccharide ligands of ZP (Topfer-Peterson et al., 2000). 
AR (Fig. 6) is defined as the physiological release of acrosomal content. It occurs in the 
female genital tract following sperm capacitation. It is a precondition to penetrate and fuse the 
oocyte ZP and to undergo the fertilization event. The cholesterol removal, elevated internal 
levels of Ca2+ and increased pH during capacitation are thought to trigger the acrosomal 
exocytosis that reduces the sperm membrane and enables to perceive the oocyte. Acrosomal 
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disruption involves the intracellular/membrane modifications and hydrolytic/proteolytic 
enzyme release. The most involved enzymes are acrosin and hyaluronidase that are required 
for oocyte penetration. AR activation and acrosomal exocytosis display the new membrane 
domains representing the new antigenic targets of the female immune system (Breitbart and 
Spungin, 1997; Patrat et al., 2000). 
AR inducing factors are zona pellucida glycoprotein 3 (ZP3) and progesterone, which is 
produced by the cumulus cells surrounding the oocyte. It has been shown that ZP binds at 
least to two sperm plasma membrane receptors, receptor activating phospholipase C (PLC) 
and tyrosine kinase receptor (TKR), which is coupled to PLC. Binding to a receptor activating 
PLC influences cAMP elevation and further PKA activation. Binding to TKR leads to the 
phosphorylation of the calcium transporter that activates phospholipase C (PLCȖ). Activated 
PLCȖ catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphoshate (PIP2) into inositol-
triphosphate (IP3) and diacylglycerol (DAG). IP3 binds to a receptor on an outer acrosomal 
membrane, resulting in Ca2+ release. DAG stimulates phospholipase A (PLA) resulting in 
fusiogenic lipids (FL) and fatty acids (FA). These substances or their derivates, e.g. 
arachidonic acid, modulate the AR. The depolarization of plasma membrane by H+/Na+ 
ionophores increases intracellular pH and activates adenylyl cyclase, which stimulates cAMP 
elevation and PKA activation. H+/Na+ exchange also alkalizes the cytosol. The increased 
concentration of Ca2+ and increased pH allow membrane fusion, followed by the AR 
(Breitbart and Spungin, 1997; Patrat et al., 2000). 
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Fig. 6 Theoretical trans-membrane and intracellular signaling of sperm acrosome reaction. ZP3: zona 
pellucida glycoprotein, R1: coupled binding receptor, TKR R2: tyrosine kinase receptor,  
PLCȖ1: phospholipase C, i pH: increased intracellular pH, AC act.: activated adenylate cyclase, 
PKA: protein kinase A, PIP2: phosphatidylinositol 4,5-bisphoshate, IP3: inositol-triphosphate, 
DAG: diacylglycerol, PLA: phospholipase A, R3: IP3 binding receptor, PD: protein derivates, 
FA: fatty acids, AR: acrosome reaction,  binding,  reaction, ion exchange,  
 stimulation. Based on Breitbart and Spungin (1997), Patrat et al. (2000).  
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2.2.4 Fertilization 
 
During sexual intercourse, millions of sperm are deposited in the vagina. In approximately 
8 seconds after ejaculation, acidic vaginal pH is changed into to basic. SF immediately 
cleaves cervical mucus to enable sperm to move. The speed of sperm depends on the 
menstrual cycle and varies from 0.2 to 0.4 mm/min. Sperm is able to survive for up to 12 h in 
the vagina. It has been proposed that 1 sperm out of approximately 5000 reaches the fallopian 
tube in 10 min (Ulcova-Gallova, 2006). 
Fertilization is defined as the union of male and female gametes to form a zygote (Fig. 7). 
Sperm is able to fertilize only a secondary oocyte at metaphase II, thus an oocyte after the 
meiotic division. The crucial step of fertilization consists of ZP penetration. Sperm has to 
pervade the oocyte-cumulus complex to reach ZP. Sperm binds to the oocyte thanks to 
components such as fukoidin and lectins. Low pH is required for dissolving this plasma 
membrane, the so-called envelope that protects the oocyte against any physical damage. The 
penetration of approximately 10 µm layer depends on the activity of sperm acrosomal 
proteases and glycohydrolases. ZP is composed of three glycoprotein layers (ZP1-3) that 
differ in their length. ZP1-3 layers represent a heterogeneous complex of asparagine (N)- and 
serine/threonine (O)-linked oligosaccharides, creating a fibrogranular layer. Sperm interacts 
with ZP either through spermadhesin, which is a lectin containing galactose, mannose or 
mannose-6-phosphate, or through proacrosin, which binds to sulphates. Sperm also binds to 
an oviductal epithelium through spermadhesin, thus it participates in the formation of the 
sperm oviductal reservoir. Once the signaling mechanism is initiated, ZP receptor kinases and 
fertility antigen A1 are autophosphorylated. With regards to the hyperactivity of flagellating 
sperm tail and its acrosomal enzymes, ZP is digested. Oocyte and sperm membranes fuse. 
After ZP penetration, sperm interacts with a vitelline membrane, which implies the 
development of an embryo. As soon as the fusion has been started through the receptors, the 
electrical block is set up. The polarity of the oocyte membrane is reversed and the polyspermy 
is blocked. The oocyte then releases its cortical granules to initiate the zona reaction, thereby 
preventing multiple sperm penetration. Cortical follicles/granules fuse with the plasma 
membrane. The cortical enzymes dissolve and remove the sperm binding receptors, thanks to 
which the vitelline envelope separates from the plasma membrane. Perivitelline space is 
created to form the fertilization membrane. When the sperm head penetrates the ovum, the tail 
separates from the rest of the sperm. Only a sperm nucleus enters the cytoplasm to fuse with 
an oocyte nucleus. After the fusion, a zygote is created. The diploid zygote undergoes division 
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to the 2-, 4- and then to 8-cell stage. The next stage is a morula, from which a blastocyst is 
formed. The blastocyst is then implanted. To summarize, the above-described process 
depends on sperm motility, sperm survival in acidic vaginal pH, cervical mucus viscosity and 
the activated female immune sytem (Yanagimachi, 1994; Topfer-Peterson, 1999; Topfer-
Peterson et al., 2000). 
 
 
 
Fig. 7 Schema of fertilization. A: acrosome reaction, B: fusion of oocyte-sperm membrane, 
C: cortical reaction, D: fusion of oocyte/sperm nuclei, A, B, C phases last 20-30 s. Based on 
Alberts et al. (2002). 
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3 FEMALE FACTOR IN REPRODUCTION 
 
 
3.1 Oocyte 
 
The oocyte (Fig. 8) is a circular cell that was first found and described by Karl Ernst Ritter 
von Baer in 1827. The oocyte is a female gametocyte also defined as a developing female 
germ cell. It is 80-200 µm in diameter with a viability of 12-24 h. It is protected by ZP and 
surrounded by the cumulus and corona cells. It is formed in an oogenesis process. It is rich in 
cytoplasm, containing a lot of yolk granules to nourish the cell at an early development 
(Mandelbaum, 2010). In comparison with sperm, the male gametocyte, the oocyte differs in 
many aspects (Tab. 3). 
 
 
 
Fig.  8 Oocyte description. (http://ldysinger.stjohnsem.edu) 
 
 
Tab. 3 Comparison of sperm and oocyte (Gilbert, 2000; Vacek, 2006) 
 
Aspect Sperm Oocyte 
size 55-65 µm 80-200 µm 
size in body one of the smallest cell one of the largest cell 
shape straight, flagellated spherical 
body parts – head, mid-piece, tail uniform 
cytoplasm small amount large amount 
nucleus condensed with no nucleoplasm bloated with nucleoplasm 
centriole present absent 
mitochondria compactly arranged scattered in cytoplasm 
motility motile (2 mm/min) immotile 
protection plasma membrane several envelops 
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Tab. 3 Comparison of sperm and oocyte (continuation; Gilbert, 2000; Vacek, 2006) 
 
Aspect Sperm Oocyte 
viability 72 h 12-24 h 
genesis spermatogenesis oogenesis 
site of creation process testis ovary 
chromosomes 23 23 
genesis beginning  puberty fetal period 
genesis end death menopause 
limitation of production millions in 3 days 1 cell in 28 days 
parent cells unlimited number can become sperm limited number can become oocyte 
optimal temperature 2 °C less than body temperature  body temperature 
 
 
3.1.1 Oogenesis 
 
Oogenesis is the female equivalent of male spermatogenesis, and describes the development 
of an immature ovum (egg cell). The egg cells are produced in the ovary (Fig. 9) in several 
stages (Fig. 10). Primary follicles contain a primary oocyte and begin to produce the sex 
hormone estrogen. A primary oocyte carries two sets of chromosomes. In the first meiotic 
division, the primary oocyte is unevenly divided into a secondary oocyte (daughter cell) and 
the first polar body. The first polar body is an apoptotic cell that cannot be fertilized by sperm 
and does not contribute to zygote, embryo or fetus development. The secondary oocyte 
contains most of the original cytoplasm, is haploid and is bigger than the first polar body. The 
secondary follicle contains a secondary oocyte and produces estrogen and progesterone. As a 
result, the Graafian follicle develops. This follicle is named after its discoverer, Regnier de 
Graaf. It contains the secondary oocyte with a formed ZP. The secondary oocyte undergoes a 
second meiotic division into an ovum and a second polar body. In reality, the secondary 
oocyte is arrested at a metaphase of secondary meiotic division (metaphase II) until 
fertilization (chapter 2.2.4 Fertilization) takes place. Arrested at metaphase II, the secondary 
oocyte is released during ovulation by follicle rupture and is trapped by the linings of 
fallopian tube, which travels toward the uterus. The ruptured follicle undergoes 
transformation into a corpus luteum, a structure of approximately 2 cm (diameter). The corpus 
luteum is formed during the luteal phase of menstrual cycle, contains carotenoids and acts as 
an endocrine structure by producing progesterone. The secreted progesterone is necessary for 
the decidualization of endometrium. Decidualization involves several significant changes in 
the endometrium to implant the embryo. As the corpus luteum degenerates, a corpus albicans 
is developed (Gilbert, 2000; Vacek, 2006; Gellersen et al., 2007).  
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Fig. 9 Oogenesis, ovarian surface cut. (http://ldysinger.stjohnsem.edu)  
 
 
 
 
Fig. 10 Schema of oogenesis, particular division. (Gilbert, 2000; Vacek, 2006) 
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3.2 Embryo development 
 
Sperm is able to fertilize the metaphase II-arrested oocyte (chapter 2.2.4 Fertilization) within 
12-24 h after ovulation. After their fusion, a zygote is formed. Two-, four- and then eight-cell 
stages turn into a morula that represents the earliest phase of embryo development (Tab. 4). 
The journey of morula to uterus lasts approximately 4 days. The following step consists of a 
blastocyst formation. The trophoblast differentiates, then digests the uterine cells and burrows 
into the wall of the uterus. The blastocyst thus tries to attach itself to the uterine wall, and is 
implanted into the higher part of uterus. Implantation is conditioned by numerous endometrial 
changes (decidualization) that enable the acceptance of the blastocyst into uterus. Endometrial 
decidualization is a post-ovulatory and pregnancy-independent process. It remodels the 
endometrium and is based on the secretory transformation of the uterine glands, influx of 
uterine NK cells, vascular remodeling and stimulated glycogen accumulation in stromal cell 
cytoplasm. The decidualized stromal cells regulate trophoblast invasion and moderate 
potential oxidative stress and maternal immune response. Maternal macrophage activity is 
suppressed based on progesterone regulation and anti-idiotypic antibodies. Implantation also 
activates placenta development. The placenta produces progesterone and estrogen to maintain 
pregnancy. It serves as a vessel for the exchange of various compounds. Carbon dioxide, urea, 
water, and hormones are all transferred from fetus to mother. In the reverse direction, oxygen, 
nutrients, water, hormones, vitamins, and minerals are transported from mother to fetus. 
During the second trimester of pregnancy, the fetus is formed and its development continues 
up to the end of the third trimester (Gilbert, 2000; Vacek, 2006; Gellersen et al., 2007).  
Pregnancy may be complicated by pre-eclampsia (PE), a disorder affecting both the mother 
and the unborn child. This life-threatening syndrome is the fatal culprit of perinatal 
morbidity/mortality, abortions and premature births. It is suggested that an inadequate 
trophoblast invasion leads to a reduced placental perfusion at the end of the first trimester, 
which is followed by endothelial dysfunction and clinical manifestation by the end of the 
second/during the third trimester. So far, the etiology is unknown and the diagnosis is still 
very complicated. The clinical manifestation varies since PE is associated with several risk 
factors such as obesity, molar pregnancy (a non-viable fertilized ovum is implanted into the 
uterus), hypercoagulation, formation of clots or diabetes mellitus. PE includes the 
manifestation of symptoms such as hypertension, proteinuria, edema, hyperuricemia.  
Additional PE symptoms including hemolysis, elevated liver enzymes and low platelet count 
are referred to as HELLP syndrome (Brazdova et al., submitted 2014a). PE syndrome is 
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considered to be a two-stage disease. The reduced placental permeability is associated with 
the first stage, causing abnormal implantation and fetal placental release into the maternal 
circulation. As a result, the maternal immune system creates antibodies against the trophoblast. 
The second phase consists of the maternal reaction to this condition. It is characterized by 
inflammation and the endothelial dysfunction of parental cells (Redman and Sargent, 2000). 
  
Tab. 4 Embryo development (Vacek, 2006) 
 
Day Process Product Localization 
0 ovulation released secondary oocyte fallopian tube 
0 fertilization zygote fallopian tube 
1-2 cleavage 2-cell stage fallopian tube 
3-4 cleavage 4-cell stage fallopian tube 
 uncompact morula formation 8-cell stage uterus 
5 early blastocyst formation blastocyst – trophectoderm, 
blastocoel, inner cell mass 
uterus 
6-7 hatching last stage blastocyst uterus 
8-9 implantation blastocyst – epiblast, hypoblast uterus 
16 development embryo uterus 
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4 INFERTILITY 
 
The World Health Organization defines infertility as a disease of the reproductive system by 
the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected 
sexual intercourse (Rowe et al., 1993). Infertility has been reported to be one of the most 
prevalent chronic health disorders regarding couples of any age (Smith et al., 2003).  
Over the last three decades, the number of documented infertility cases has increased. 
Decreased fertility is associated with other health issues, age, life style and environment. The 
agent of infertility for a couple is the male partner about 40% of the time, the female partner 
about 40% of the time , and about 20% of the time the fertility problems are shared by both 
the man and the woman. Factors contributing to infertility involve congenital, hormonal, 
morphological and immunological disorders. Infertility may be also related to other diseases 
such as severe avitaminosis, severe renal impairment, cancer and cachexia due to malnutrition 
or tumor (Doherty and Clark, 2006).  
The main disorders involved in infertility include pathologic spermiogram, ovulation 
problems/anovulation, tubal diseases, pelvic adhesion/endometriosis, cervical factors and 
idiopathic reasons – i.e. unexplained infertility. However, a single specific cause of infertility 
is never certainly diagnosed (Gleicher and Barad, 2006; Siristatidis and Bhattacharya, 2007). 
 
 
4.1 Unexplained infertility 
 
Unexplained infertility (UI) is diagnosed to a couple when the standard investigations 
including semen analyses and tests of ovulation and tubal potency do not provide specific 
results or do not provide evidence of any abnormality (Crosignani et al., 1993). Several 
reports (Crosignani et al., 1993; Gleicher and Barad, 2006; Siristatidis and  
Bhattacharya, 2007) suggest that the diagnosis of UI is subjective and that UI is often 
misdiagnosed for endometriosis, tubal infertility, premature ovarian ageing and immune 
infertility. The prevalence of UI reaches up to 30% of infertile couples with regards to 
standard investigation.  
Severe endometriosis affects the fertility potential. Mild endometriosis is not, however, 
associated with infertility in the absence of secondary organic disruption. It has been reported 
that approximately 20% of infertile females suffer from tubal disease, either distal or peritubal 
(Smith et al., 2003; Gleicher and Barad, 2006). Follicle number is genetically dependent. 
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Female subfertility caused by poor ovarian reserve is declared when the remaining follicle 
amount represents a fraction of the original value. This state becomes crucial at the age of 30. 
The critical point of ovaries is reached at the age of 38-40 when the follicle number decreases 
to approximately 25 000. At the age of 50, the amount reduces to approximately 1000 
follicles (Nikolaou and Templeton, 2003). In some women, the so-called poor ovarian 
response has been noticed when the ageing ovary produces fewer follicles, follicles growth is 
poor, and follicular atresia occurs (Siristatidis and Bhattacharya, 2007). 
Immunological tolerance plays a key role in UI. Molecular and cellular endometrial 
deficiency resulting in an implantation failure can be related to UI since the natural 
immunosuppression does not prevent maternal immune rejection. T regulatory cells (Treg) are 
believed to protect the fetus from an immune attack. Treg cells function in immune tolerance. 
The diminished production of Treg from naïve T helper (Th) cells is determined based on the 
expression of transcription factor Foxp3 (Agnello et al., 2003; Sumerset et al., 2004). UI is 
not only linked to Treg differentiation, and thus to immune suppression failure, but also to its 
recruitment into an implantation site. This is caused by the reduced expression and 
insufficient function of lymphocyte and chemotactic agents present in uterus. Since Treg 
differentiation is regulated by TGFȕ, the idiopathic infertility may be related to a reduced 
availability of this factor. A lack of TGFȕ results in insufficient Treg induction. Diminished 
CD4+CD25+ Treg population, the lower expression of Foxp3 and the failure of lymphocyte 
adherence and chemotaxis seem to play a negligible role in primary cause of UI (Bommireddy 
and Doetschman, 2004; Jasper et al., 2006).  
 
 
4.2 Immune infertility 
 
During the early phase of the primary immune response after exposure to an antigenic agent, 
IgM antibodies are produced. The so-called antibody switch into IgG and IgA is induced at 
the late phase of primary immune response or after repeated exposure to the same antigen 
(Batard et al., 1993). After chronic antigen exposure, IgG1 and IgG4 become the 
predominantly produced subclasses of IgG isotype. IgG4 is a unique antibody acting as an 
anti-inflammatory immunoglobulin and a blocking antibody toward IgE. It yet remains 
unclear whether IgG4 is a protective or a sensitizing antibody (Aalberse and Schuurman, 2002; 
Guma and Firestein, 2012). Some studies (Schroeder and Cavacini, 2010; Tamayo et al., 2012) 
proposed that IgG1 and IgG3 are, in general, induced in response to antigens of a protein 
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nature while IgG2 especially and IgG4 to antigens of a polysaccharide character. Furthermore, 
the IgA1 subclas may generally recognize the antigens of a protein and glycoprotein nature. 
Antibodies directed against antigens of a polysaccharide character may occur in the IgA2 
subclass (Kutteh et al., 1994; Schroeder and Cavacini, 2010; Tamayo et al., 2012). 
Immune/immunological infertility is diagnosed when spontaneously produced antibodies 
bind to the antigens occurring on either the male or female gametocyte. In particular, 
antibodies bind to seminal proteins or structures present on the sperm or oocyte. So far, ASA 
have been observed more frequently than anti-oocyte antibodies (AOA) and are related to 
some cases of unexplained infertility (Bohring and Krause, 2003).  
 
 
4.2.1 Anti-sperm antibodies 
 
Sperm antigenicity within the animal kingdom was first described in 1899. In 1932, Baskin 
observed circulating antibodies against sperm and finally in 1954, Rümke observed and 
described the first type of anti-sperm antibodies. ASA have cytotoxic, immobilizing and 
agglutinating (Fig. 10) functions. The sperm-agglutinating type is most abundant among the 
European population and causes the so-called shaking phenomenon, while the sperm-
immobilizing type is more prevalent in the Asian population. ASA are detectable on the 
systematic (blood and lymph) as well as the local level (SF, cervical-vaginal mucus). In 
general, the IgG isotype of ASA is mainly related to blood circulation and the IgA isotype to 
mucosal immunity in women. In men, IgG and IgA fractions are most prevalent in SF, while 
IgG and IgM isotypes prevail in serum (Ulcova-Gallova, 2006).  
Sperm carries the paternal genome further displayed on an oocyte and has a very 
heterogeneous antigenic content. Since sperm has auto-antigenic (auto-immunization) as well 
as iso-antigenic (iso-immunization) potential, it is capable of inducing the production of 
sperm-reactive T-cells in men as well as in women. It is not a single ASA that influences 
fertility, but more likely an ensemble of ASA that causes infertility. It has been postulated that 
a single sperm antigen is not able to cause infertility. Further, it has been reported that not all 
ASA, regardless of being produced in women or men, influence the fertility potential since 
the cognate antigen is not necessarily involved in the fertilization process (Wang et al., 2009; 
Haidl, 2010; Sedlackova et al., 2010; Bronson, 2011).  
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A highly heterogeneous sperm antigenic content could even be modified during maturation 
and ejaculation based on antigen sequestration. Newly expressed antigens could be then in 
contact with any immunocompetent cells. For example, a sperm membrane-incorporated 
fibronectin exhibits changes in regional antigenic expression during sperm maturation, 
whereas secreted fibronectin is a product of male accessory sex glands and can be attached to 
sperm tails during ejaculation (Kosanovic and Jankovic, 2010). Considering gastrointestinal 
exposure, ASA formation may be operative (Bohring and Krause, 2003).  
In men, sperm germ cells are protected in the testis from an auto-immune attack by the 
blood-testis barrier. When the barrier is disrupted, ASA are detectable in blood serum, 
seminal plasma or directly attached to sperm surface membrane. An increased risk of ASA 
formation may follow the congenital absence of reproductive tract components. ASA are 
mostly associated with genital inflammation or infection (e.g. orchitis), epididymis trauma, 
genital surgery, cryptorchidism and varicocele (Kosanovic and Jankovic, 2010). The theory of 
auto-immune disease was supported by Omu et al. (1999) by proving that ASA formation is 
related to certain human leukocyte antigen (HLA) classes.  
 
 
 
Fig. 11 Spermagglutinating effect of ASA. Sperm agglutination by head (A), tail (B), tail end-piece (C) 
and simultaneous agglutination by head and tail (D). (Ulcova-Gallova, 2006) 
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In women, the failure of natural tolerance may lead to sensitivity resulting in sperm 
elimination. ASA can induce antibody-mediated infertility through various pre/post-
fertilization processes, such as sperm motility and agglutination, cervix mucus penetration, 
capacitation, acrosome reaction, zona pellucida binding and penetration, oolema binding, 
sperm-oocyte fusion and embryo implantation (Brazdova et al., 2012b;  
Brazdova et al., 2013b). The active local immuno-regulatory mechanism is based on vaginal 
and cervical tissues having an active and sensitive mucosal immune system, by which the 
fertility potential is affected. This explains the rather high percentage of infertile women in 
association to the local reactions leading to an inflammation as well as to high levels of serum 
anti-semen antibodies. Serum ASA are related to the long-term exposure of female to sperm 
and seminal deficiency in immuno-suppressive factors (Mazumdar and Levine, 1998;  
Bohring et al., 2001).  
As it was previously mentioned, sperm is able to induce the production of sperm-reactive 
T-cells, and thus is opsonized and then targeted by the leukocytes (sperm-cytotoxic effect) 
(Kurpisz and Kamieniczna, 2009; Sedlackova et al., 2010; Bronson 2011). Nevertheless, there 
is evidence of ASA occurrence in fertile women and men. Some fertile individuals are 
positive in serum sperm agglutinins. It is suggested that these ASA are not clinically 
significant, but rather a physiological effect without a pathologic background. In this case, 
they might be considered as “natural” ASA (Chamley and Clarke, 2007;  
Kurpisz and Kamieniczna, 2009). The natural antibodies are produced in the absence of 
immunization, antigen exposure. They are produced by auto-reactive B-cells that were 
stimulated to grow. The correlation remains constant from early childhood to adulthood. In an 
adult serum, the prevalent percentage of natural antibodies belongs to autoantibodies of IgM 
and IgG isotype. This implies that auto-reactive T-cells contribute to a repertoire of auto-
reactive B-cells under physiological conditions. Autoantibodies are polyreactive, help remove 
senescent molecules and cells, participate in immune auto-treatment of cancer and, 
hypothetically, may be considered as precursor antibodies (Bernabe et al., 1981;  
Avrameas, 1991; Kazatchkine and Kaveri, 2001). The polyreactive character of such 
precursor antibodies may also play a part in cytotoxic reaction during early fertilization 
associated with infertility.  
On the other hand, ASA are of great interest concerning immuno-contraceptive effect. The 
immuno-contraceptive potential of ASA has already been studied (Krause and Naz, 2009; 
Naz, 2011). It is limited by its specificity and possible role in the fertilization events. Of 
course, this potential immuno-contraception is of risk with regards to the induced high titers 
30 
 
of sperm specific T-cells. An antigenic complex prepared from the whole semen carries the 
risk of hypersensitivity to seminal fluid antigens or the risk of mimicry of various somatic 
cells. Direct ASA targeting has not yet been reported. Currently, ASA-mediated infertility is 
treated with systematical immunosuppression. The treatment of female immune infertility by 
use of monoclonal antibodies might be applicable but simultaneously complicated  
(Domagala and Kurpisz, 2004). Not only are sperm antigens considered in an immuno-
contraceptive research, but ZP antigens are also taken into account forming a complex antigen 
mixture. A fertility vaccine may also operate on the level of hormones. Antibodies precisely 
directed to a ȕ-subunit of human chorionic gonadotropin (hCG) may block the early gravidity 
stages (Ulcova-Gallova, 2006). 
 
 
4.2.2 Association of seminal components with female sensitization 
 
It has been shown that SF, a nutritious transport buffering sperm medium, has a built-in 
mechanism for preventing an immunological sensitization of the female. This protective 
system exists due to the presence of immune inhibitors originating in the male sex accessory 
glands (Prakash, 1981). Some seminal constituents, such as cathepsin D, are able to degrade 
vaginally exposed proteins that may be involved in antibody formation related to immune 
infertility. Furthermore, the low molecular weight proteins are of need in oocyte and sperm 
fusion as degradation products (Pardesi et al., 2004). Seminal ZAG, a 40 kDa 
multidisciplinary protein, has been reported as a novel adipokine playing a significant role in 
fertilization, lipid mobilization, and peptide/antigen/ligands binding. ZAG may participate in 
the expression of female immune response since the fold is similar to major 
histocompatibility complex (MHC) I antigen-presenting cells. ZAG has proved to be an IgG-
binding protein related to a pathophysiological iso-immunization. It may also have a 
protective character, as it belongs to the immunoglobulin gene superfamily and thus blocks 
the newly created female anti-semen antibodies (Hassan et al., 2008; Brazdova et al., 2013b). 
An antibody fraction interacting with a seminal antigen targets most of seminal proteins 
adsorbed on sperm. However, SF induces the recruitment of macrophages and dendritic cells 
into cervical and endometrial tissues. SF has been heavily involved in the rare IgE-mediated 
reaction to semen (Weidinger et al., 2006; Brazdova et al., 2012a).  
 
  
31 
 
4.2.3 Auto-immune aspects in infertility 
 
Auto-immune phenomena have been previously associated with an increased prevalence of 
female immune infertility. This finding names anti-phospolipid, anti-nuclear, anti-thyroid,  
anti-annexin V, anti-protombin, anti-laminin, anti-zona pellucida antibody formation, as well 
as a high level of NK cells as the risk factors but not as those pathognomonic  
(Gleicher and Barad, 2006).  
ZP, as the protective layer, is composed of glycoproteins. It represents a broad antigenic 
content. Antibodies against ZP prevent sperm from penetrating it. Anti-ZP autoantibody 
concentration can be elevated if the shape of ZP is abnormal (deformed, thickened, or 
thinned). These antibodies interfere with the implantation process since ZP protects the 
fertilized oocyte up to the 7th day after fertilization and until embryo hatching. ZP is, during 
this time, thickened. ZP-specific antibodies are detectable in follicular and peritoneal fluid 
and cervical mucus in IgG, IgA and IgM isotypes (Ulcova-Gallova, 2006).  
Anti-phospholipid antibodies (APA) were first found by Wasserman in 1906 and since that 
time have been associated with miscarriage, intrauterine fetal death and placental thrombosis. 
These components of the female immune system are autoantibodies directed against the 
negatively charged parts of phospholipids, and in particular phosphatidylserine, 
phosphatidylinositol, phosphatidylethanolamine, annexin V, cardiolipin, and ȕ2-glycoprotein. 
APA are mostly produced in the IgG fraction accompanied by IgA and IgM. 
Phosphatidylserin-specific APA cause fetus hypotrophy as a consequence of placental 
vascular damage. However, mother protection results in the higher production of anti-
coagulating factors. Furthermore, the risk of spontaneous abortion is higher in the presence of 
anti-coagulating antibodies. Antibodies specific to annexin V and placental anti-coagulating 
protein are risk factors in reproductive failure. These IgG antibodies are detectable in 5-6% of 
women diagnosed with pregnancy loss, in 8-10% of women after unsuccessful in vitro 
fertilization (IVF), in 1% of not pregnant and healthy women and in 0% of pregnant women 
without pathophysiologic aspect. Complex complication is called anti-phospholipid syndrome 
(APS), also known as Hughes syndrome. It may cause hyper-coagulation leading to rapid 
organ failure. Since APA have high affinity to phosphatidylserin present on trophoblasts, APS 
seems to be involved in the mental retardation of newborn children (Ulcova-Gallova, 2006; 
Ruiz-Irastorza et al., 2010).  
The trophoblast expresses the major histocompatibility antigens on its surface. They are of 
maternal and paternal origin. Paternal patterns induce allo-immunity. Formed anti-paternal 
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cytotoxic antibodies usually implicate spontaneous abortion. Other factors involved in this 
complicated immune reaction are NK cells, alteration in Th1 and Th2 ratios and abnormal 
HLA-G expression (Shetty and Ghosh, 2009).  
Endometrium-specific antibodies are inter alia associated with the polycystic ovary 
syndrome (PCOS) that is mainly classified as an endocrine genetic disorder. Women suffering 
from PCOS have usually problems getting pregnant. PCOS is known as Stein-Leventhal 
syndrome described in 1935. It is characterized by enlarged ovaries caused by cysts, irregular 
ovulation, irregular or no menstrual periods and increased androgen level. With regards to 
androgen level, PCOS is associated with hirsutism. On the other hand, it is associated with 
obesity, type 2 diabetes and high cholesterol level (Ulcova-Gallova, 2006; MFMER, 2013).  
Pregnancy is complicated by a serious gynecological complication called endometriosis. It 
affects up to 10% of women in reproductive age and 25% of women diagnosed with 
endometriosis are infertile. Its etiology is unknown. This disorder occurs when the lining of 
the uterus grows in other areas outside of uterus. Ectopic bearings react on the hormone level, 
thus are subject to the menstrual cycle. Created cysts occur on ovaries, fallopian tubes, 
peritoneum, cervix and in vagina. Peritoneal endometriosis is characterized by retrograde 
menstruation causing secondary inflammation. Factors typical for such a condition are  
the high level of autoantibodies, presence of T-lymphocytes in peritoneal fluid and elevated 
level of NK cells (Nisolle et al., 1990; Bulletti et al., 2010). 
  
 
4.3 Mucosal immunity of the female genital tract 
 
The mucosal immune system operates on a local level and is represented by lymphoid tissues 
in mucosae and external secretory glands. It limits the access of environmental antigens, by 
which the fertility potential is significantly regulated as well. Any inert antigen is attacked by 
these secreted agents of protection. It restricts and/or avoids penetration in the systematic 
compartment. The female genital tissues and secretion (vaginal washes and cervical mucus) 
provide protection that differs from systematic reactions by the cell types involved and by 
their products, antibodies. However, it is the initial antigen exposure to mucosae that leads to 
the systematic T-cell hypo-responsiveness (Woof and Mestecky, 2005; Mestecky et al., 2007). 
Mucosal immunity in the female genital tract is influenced by the level of antibodies, 
cytokines and hormones. Humoral immune defense displayed in musocal tissue surfaces is 
comprised of the IgG, IgA and IgM antibody isotypes. IgG, IgA and IgM levels are dependent 
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on the menstrual cycle, and so are influenced by hormones. IgA and IgG reach maximum 
concentration before ovulation, which is linked to an increased level of interleukin 1 
component ȕ (IL-1ȕ). Particularly, estrogen causes a higher expression of secretory IgA (S-
IgA), thereby increasing the rate of selective transport. This method of regulation is 
responsible for antibody-isotype distribution and the characteristics thereof, including their 
individual properties and the transport of immunoglobulin-containing cells, antigen-
presenting cells (APC), CD4+ and CD8+ cells in the vagina, uterus and fallopian tubes  
(Kutteh et al., 1996). In addition, it has been shown (Franklin and Kutteh, 1999) that oral 
contraception influences IgA as well as IgG populations in cervical mucus. It is around one 
third larger than in the cervical mucus of naturally cycling women. Further, the vaginal 
washes of women on oral contraception present an elevated level of IgG in comparison to IgA. 
Several observations showed (Kutteh et al., 1996; Mestecky and Fultz, 1999) that the 
concentration of these antibodies decreases as IgG>IgA>IgM. This relationship is linked to 
the presence of IgG/A/M-producing cells. The uterine endocervix contains the highest amount 
of IgG- and IgA-secreting cells. Cervical mucus contains higher levels of IgG than IgA, both 
of which are locally produced. By contrast, women on oral contraception have IgA as the 
predominant antibody present in cervical mucus. Among the mentioned three isotypes, IgM is 
the least efficiently transported antibody. The mucosal IgA antibodies are selectively 
transported for external secretion based on a receptor-associated mechanism. The distribution 
of IgG subclasses in mucosal secretion displayed concentrations proportional to that of 
plasma. IgD occurs rarely or in very low concentration in external mucosae. The level of IgE 
depends on the allergenic nature of presented antigen (Woof and Mestecky, 2005).  
Despite the low IgA affinity, the avidity is high regarding multi-binding sites. Proteolytic 
enzymes usually degrade environmental antigens leading to a relatively low mucosal 
absorption rate. IgA itself is resistant to enzymes of proteolytic character. It has been 
suggested that certain amounts of non-eliminated antigens circulate in the complex with IgA, 
which further activates the systematic immune response. It is less probable that an antigen 
only just entering the mucosal tissue could circulate on its own (Mestecky and Fultz, 1999; 
Mestecky et al., 2007; Corthesy, 2007).  
IgA is a multivalent antibody existing in two subclasses, IgA1 and IgA2. While IgA1 
responds to viral (protein) antigens, IgA2 binds to lipopolysaccharide or polysaccharide 
structures. IgA has an anti-inflammatory activity evidenced by the inhibition of complement 
activation and by a diminishing effect on NK cells. These properties might inhibit an early 
and precise diagnosis as no inflammatory marker may be detected. In cervical mucus as well 
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as vaginal washes, IgA1 concentration is equal to that of IgA2. S-IgA is locally produced by 
sub-epithelial plasma cells. Most of the time, it is a polymeric molecule that corresponds with 
IgA2 since IgA1 is rather monomeric. It has been suggested that cervical mucus contains about 
80% of the polymeric form and vaginal wash about 50% (Kutteh and Mestecky, 1994;  
Kutteh et al., 1996; Woof and Mestecky, 2005). The IgA antibody can degranulate 
eosinophils that cover mucosal surfaces. This pathology is observed when natural immune 
tolerance is disrupted. (Further reaction may evoke allergic reaction to the presented antigen 
such as seminal and/or sperm structure. Semen rejection at the level of mucosal immunity 
does not have to be displayed on the systematic level (Woof and Mestecky, 2005). 
Woof and Mestecky (2005) discussed the protective character of IgA. Its protective role is 
observed in an antibody-dependent, cell-mediated cytotoxicity, opsonization, the activation of 
innate humoral factors, and the removing and further elimination of already formed immune 
complexes within epithelial cells and lamina propria. It is known that IgA is able to diminish 
the partial and total absorption of the antigen on mucosal tissues. In comparison with IgG, 
which after antigen-recognition activates complement resulting in inflammation, IgA acts as 
an inhibitor to directly avoid the adherence of antigen (Russell et al., 1997). S-IgA in a 
complex with antigen is not able to efficiently activate the complement pathway. Exclusivity 
of IgA is related to its natural occurrence and polyreactivity. Another characteristic of its 
protective capacity is related to the cell line that produces the IgA subclasses. IgA1 originating 
in B1 cells are of low affinity but wide specificity. In contrast, S-IgA derived independently 
from B1 and B2 cells do not differ in antigen specificity (Quan et al., 1997).  
 
 
4.3.1 Cervical Mucus 
 
The uterine cervix participates in the local immune reaction by the application of 
immunoglobulin-producing cells in a complex mixture known as cervical mucus/fluid/plasma, 
which is located in and around the cervix. Cervical mucus is composed of up to 90% water, 
depending on the menstrual cycle, which determines the quantity as well as the quality of 
cervical mucus. Its composition is based on a glycoprotein web filled with mucus rich in 
immune-competent proteins, electrolytes (calcium, sodium and potassium), simple sugars 
such as fructose and glucose, amino acids, C3 and C4 complement components, Th1 and Th2 
cytokines, the prostaglandins of E series, and trace elements (zinc, copper, iron, mangan, 
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selenium). An imbalance is frequently associated with immune infertility and spontaneous 
abortion (Moghissi, 1972; Schumacher, 1988; Cibulka et al., 2005; Ulcova-Gallova, 2010). 
Optimal pH ranges from 7.4 to 9.6. The pH of cervical mucus is alkaline during ovulation 
to allow sperm survival due to elevated levels of water and electrolytes. After menstruation, 
cervical mucus becomes rather acidic. Acidic pH is characteristic for vaginal mucus as well, 
ranging from 3.7 to 4.5 (Gruberova et al., 2006).  
The basic role consists of a barrier that prohibits anything from entering the uterus. It is 
associated with “stick and thick” properties. Cervical mucus acts as a natural lubricant due to 
its glycerol content. The apparent amount of cervical mucus is not hormone-dependent. The 
mucus also functions as a transport and nourishing medium for sperm by being less 
concentrated, transparent with a lower amount of immune-competent agents and a high 
fructose level, which is essential for an efficient sperm metabolism. The sugar level is 
progesterone dependent. On the other hand, the cervix always acts as a reservoir for sperm 
after sexual intercourse. Regarding iso-immunization during the entire menstrual cycle, 
cervical mucus contains the antibodies directed toward sperm. Their amount is then crucial 
for sperm-cervical mucus penetration and following fertilization. ASA-positive female 
patients have been commonly diagnosed with immune infertility. Approximately 5-10% of 
infertile female patients are positive in cervical ASA. An iso-immunization rate is observed 
by probing the local ASA level, which will determine an appropriate treatment  
(Moghissi, 1979; Schumacher, 1988; Cibulka et al., 2005). It has been shown  
(Ulcova-Gallova, 2010) that ASA present in cervical mucus are of agglutinating character. 
These locally produced ASA do not differ from those systematically produced thus they affect 
sperm capacitation, acrosome reaction, and may interfere with zona pellucida penetration as 
well as embryo implantation (Livi et al., 1991). The peak of ASA in IgA and IgG fraction is 
reached at the luteal and follicular phases of the menstrual cycle. In contrast, their levels are 
lowest during ovulation. This peak in ASA concentration is related to the highest level of 
estradiol, usually observed one day before ovulation (Franklin and Kutteh, 1999). However, 
Schumacher (1973) demonstrated that local immunoglobulin production could be diminished 
in women on oral contraception. The study demonstrated the impact of oral contraception 
with respect to estrogen-dependent, decreasing antibody level in cervical mucus and then with 
regards to progestin-dependent (a synthetic progestogen of progestational effects similar to 
progesterone), increasing antibody level (Schumacher, 1973). This finding supports the fact 
that cervical immunity before ovulation is influenced by estrogen and after by progesterone.  
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4.4 Treatment of female infertility 
 
Modern era progress in medicine allows highly individualized and efficient access to 
infertility treatment. Despite the fact that the cause of female infertility can be difficult to 
diagnose, many diagnostic methods and treatment approaches are available. Effective 
treatment of reproductive failure depends on its cause. Concerning precise diagnosis, 
reproductive immunologists attempt treatment to restore fertility usually by medication, 
surgery or reproductive assistance by sophisticated techniques. Prior to determining the nature 
of an individual infertility disorder and choosing a suitable way of its treatment, a couple has 
to be thoroughly examined. A non-invasive method, such as an evaluation of sperm quality, 
represents the major male examination. Based on volume, color, consistency, sperm motility, 
sperm number, the number of defective forms, additive cellularity (leukocytes and 
lymphocytes), pH and ASA level, the semen type is specified (chapter 2, Tab. 1, 2). Women 
are examined by ultrasound, laboratory and cytology tests in order to determine ovulation 
disorders, hormonal imbalances, and external and internal genital abnormalities. Basal 
hormone levels in the blood are examined between the 2nd and 5th day of the menstrual 
cycle. This screening includes follicle-stimulating hormone (FSH), prolactin (PRL), 
triiodothyronine (T3), thyroxine (T4), thyreotropin (THS) and estradiol (E2). The state and 
patency of fallopian tubes can be tested by ultrasonography or when necessary by 
laparoscopy. To examine uterine cavity, hysteroscopy may be suggested. In addition, 
bacteriological culturing from the canal of uterine cervix is performed to exclude any 
infection of internal genitals. In any case, the treatment is psychologically and physically 
arduous. It also involves considerable financial commitments (Ulcova-Gallova, 2006; 
Rezabek, 2008; Pandey et al., 2012).  
The treatment of women diagnosed with immune infertility can be described in three steps, 
where each proceeding step follows the failure of previous one. Fertility can be restored by 
stimulated ovulation with fertility drugs, surgery or reproductive assistance, all of which carry 
several risks. Women of ages less than 30 are advised to use the so-called condom therapy for 
3-6 months in order to avoid the contact of female immune system and sperm. This basic 
approach is combined with other methods of treatment. As a result of an appeased immune 
system, success reaches up to 40% (Ulcova-Gallova, 2006.) 
Since the majority of locally produced ASA belongs to IgA antibodies - particularly to 
IgA1, another type of infertility treatment might be suggested (Kutteh et al., 1994). The 
intravaginal administration of selectively cleaving IgA proteases would block present ASA 
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and further sperm agglutination would not happen. A proteolytic IgA1 cleavage is specific to 
prolin-serin or prolin-threonin bonds within the IgA1 hinge region. The generated noncovalent 
Fab fragments would avoid an antigen binding to Fc fragments of cleaved IgA. This theory 
speculates about the invasion of other ASA isotypes, mostly the IgG portion, present in 
cervical mucus and vaginal washes, as well. Based on the IgA predominance, most of the 
semen epitopes may be blocked by the cleaved Fab/Fc fragment of IgA. However, the 
question of ASA in IgA2 isotype and its inactivation remains unanswered  
(Bronson et al., 1987; Russell and Kilian, 2005).  
 
 
4.4.1 Fertility drugs 
 
Immunotherapy is often chosen to modulate the organism to decrease the level of 
pathophysiological antibodies such as ASA and AOA. Nonspecific local or systematic 
approaches consist of corticosteroid administration. An application of cervical pessary with 
corticosteroids is appropriate for female patients having ASA only in the cervical mucus and 
not circulating ASA. Plasmapheresis is another option to decrease the concentration of 
antibodies potentially related to infertility. The advantage of this technique is high efficiency, 
while the chief disadvantage is short-term effect. Plasmapheresis has to be, therefore, 
combined with immunosuppression (Haas et al., 1980; Ulcova-Gallova et al., 1990).  
Fertility drugs aim to regulate or trigger ovulation. Ovulation is commonly induced by 
anti-estrogens, e.g. clomiphene citrate. Clomiphene citrate is orally administered and 
stimulates the release of gonadotropin releasing hormone (GnRH). The cascade continues by 
a triggering of hypophysis to secrete FSH and luteinizing hormone (LH), both of which 
finally stimulate the growth and maturation of follicles in the ovaries. When clomiphene 
citrate fails and/or hypophysis cannot produce LH and FSH on its own, a gonatropin-injected 
treatment follows. Gonadotropins, FSH and LH, affect follicular maturation directly in the 
ovaries. Hormone hCG may replace LH as it mimics LH effect. Fertility drug utilization 
carries the risk of multiple pregnancies that increases the possibility of premature labor, low 
birth weight and later developmental problems. A gonatropin-injected treatment may cause 
the so-called ovarian hyperstimulation syndrome, wherein women suffer from swollen ovaries 
and associated pain, bloating, nausea, vomiting and diarrhea. All symptoms or even individual 
symptom can last for weeks. Long term hormonal treatment lasting 12 or more months has 
been linked to ovarian cancer later in life. However, it has been shown that women who have 
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never been pregnant are exposed to an elevated risk of ovarian cancer. Ovulation and/or 
conception may be negatively affected by any anatomy abnormalities such as an abnormal 
uterine shape, endometrial polyps, the deformed shape of uterine cavity, pelvic or uterine 
adhesions, fallopian tube blockage, and hydrosalpinx (distally blocked fallotropian tube, filled 
with water). Laparoscopy, hysteroscopy, tubal ligation, reversal micro-surgery and tubal 
surgery are the most used diagnostic techniques. If the blockade is not able to be corrected, 
the techniques of artificial insemination are recommended (Doherty and Clark, 2006; Rezabek, 
2008; MFMER, 2013). 
 
 
4.4.2 Reproductive assistance 
 
The assisted reproductive technologies (ART) represent an immense step forward in 
infertility therapy. ART have in common the manipulation of stem cells to successfully 
achieve pregnancy. It includes in vitro fertilization (IVF), gamete intra-fallopian transfer 
(GIFT), zygote intra-fallopian transfer (ZIFT), from which IVF is the most frequent approach 
of ART. GIFT treatments are chosen in less than 2% of all ART procedures, ZIFT in less than 
1.5%. IVF was developed by Robert Edwards who was awarded the 2010 Nobel Prize for the 
development of human IVF therapy. The famous date of the world‟s first “tube baby” is July 
25th, 1978. IVF is combined with fertility drug therapy in order to evoke ovulation. The 
stimulated ovaries produce oocytes that are further aspirated. These oocytes are treated under 
special conditions with sperm until fertilization takes place. A certain amount of embryos is 
then placed into the uterus. It has been shown that women undergoing IVF produce the 
antibodies against zona pellucida. Their level increases with the repeating rate of unsuccessful 
IVF. These antibodies are detected in the patient sera but not in the cervical mucus. Isotypes 
occur following the relationship: IgG>IgA>IgM>IgE. An extracorporeal conception competes 
with an intra-uterine insemination (IUI) that represents less arduous methods for the female 
patient. IUI involves placing millions of washed sperm (normozoospermic type) into the 
uterus close an ovulation time, by which it is avoided the contact with cervix and its 
immunocompetent cells. It is commonly used in the case of unexplained infertility and may 
be appropriate procedure for sperm donor conception (Doherty and Clark, 2006; Rezabek, 
2008; MFMER, 2013).  
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4.4.3 Intravenous immunoglobulins 
 
Intravenous immunoglobulins are defined as plasma pools obtained from thousands, and 
sometimes hundreds of thousands, of healthy blood donors. Such a large set of individuals 
increases the potential high variety of antibodies present in plasma with specificity against 
bacterial, viral, and parasitic antigens. On the other hand, it carries the risk of diluting the 
amount of specific antibodies of rare activity. IVIg is a substitutive treatment in primary and 
secondary immunodeficiencies. It is used in several auto-immune as well as inflammatory 
diseases, and was put into medical practice 25 years ago (Bayry et al., 2003; Kaveri, 2012).   
IVIg was, for the first time, successfully demonstrated as a valuable substitutive treatment 
in auto-immune disease, particularly in idiopathic thrombocytopenic purpura. The range of 
immune disorder has been enlarged since that time, as it has been established in the treatment 
of Guillain-Barré syndrome, Kawasaki disease, chronic inflammatory demyelinating 
polyneuropathy, myasthenia gravis, multifocal neuropathy, corticosteroid-resistant 
dermatomyositis, antineutrophil cytoplasmic auto-antibody-positive vasculitis, auto-immune 
uveitis, multiple sclerosis, anti-factor VIII auto-immune disease, polymyositis, anti-
phospholipid syndrome, recurrent spontaneous abortion, systemic lupus erythematosus (SLE), 
insulin-dependent diabetes mellitus, Crohn‟s disease and in the prevention of graft-versus-
host disease and others. Usually, IVIg is administered in the dose of total 2 g/kg over 2 or 5 
consecutive days. Despite the promising effect of IVIg, precise disease diagnoses and a 
detailed knowledge of immunology, the mechanism of IVIg action remains unexplained 
(Kazatchkine and Kaveri, 2001; Bayry et al., 2003; Bayry et al., 2011). 
The mode of IVIg action is complex. It operates on several levels: Fc receptors, 
inflammation, B-cells and antibodies, T-cells, and cell growth. The immunoregulatory effect 
regarding Fc receptors consists of their blockade on macrophages as well as on effector cells. 
IVIg induces antibody-dependent cellular cytotoxicity. It reduces inflammation by the 
induction of anti-inflammatory cytokines, inhibition of activated endothelial cells, attenuation 
of complement-mediated damage and neutralization of microbial toxins. In general, the anti-
inflammatory effect depends on interaction with endothelial cells and cytokines. IVIg triggers 
the activation and effect of B and T lymphocytes and interferes with APC. It expands Treg. 
Another attribute is comprised of the provision of anti-idiotypic antibodies. IVIg neutralizes 
T-cell superantigens, pathologic antibodies and then circulating auto-antibodies by anti-
idiotypes. It selectively down/up-regulates antibody production, apoptosis and the production 
of Th cell cytokines. Specifically, it decreases tumor necrosis factor α (TNFα), IL-1ȕ, and it 
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increases interleukin 1 receptor agonist (IL-1Ra). It acts also as an inhibitor of lymphocyte 
proliferation. The immune system interacts with IVIg through its Fc receptors, T and B 
lymphocytes, NK and dendritic cells (DC), complement, cytokines and granulocytes. In detail, 
DC differentiation and maturation are inhibited in vitro by high IVIg dosage. IVIg also blocks 
the secretion of IL-12 by matured DC while elevating IL-10 secretion. The results of IVIg 
utilization in therapy depends on a synergic effect with the immunomodulatory components 
of individual patients. In order to understand the IVIg operation, attention is paid to the 
sialylated Fc fragment of IgG (Bayry et al., 2003; Galeotti et al., 2009).  
Nowadays, IVIg is routinely and commercially prepared. This product contains mostly 
polyspecific IgG antibodies. The subclass distribution mirrors the normal human serum. The 
trace components are immunoglobulin A and M, soluble CD4, CD8, HLA molecules. The 
half-life of IVIg infused to an immuno-competent person is approximately 3 weeks  
(Kazatchkine and Kaveri, 2001).  
IVIg therapy is relatively safe. High doses may evoke some side effects such as headache, 
fever, nausea, emesis, hypertension, and muscle cramps. Severe reactions include throat/chest 
tightness, chills, dizziness, breathlessness and in rare cases also collapse or anaphylactic 
shock. The third generation of IVIg, nowadays present in the market, has been immensely 
improved. After hepatitis C contamination in 1993, IVIg therapeutics avoid the risks of prion 
disease since intact IgG antibodies are isolated with particular steps of viral 
inactivation/elimination thanks to low pH and caprylic acid treatment, pasteurization, and 
nanofiltration (Radosevich and Burnouf, 2010; Bayry et al., 2011). 
 
 
4.4.3.1 IVIg and infertility related disorders 
 
IVIg may represent a potential therapeutic strategy in fertility disorders related to an immune 
system with an auto-immune background. SLE is considered as the most serious disorder 
related to infertility. It is a multifactorial auto-immune disease characterized by the presence 
of autoantibodies linked to nuclear antigens. It is characterized by system failure that can 
affect any part of the body. Created immune complexes precipitate. This action further 
activates an immune response. Since SLE is associated with fetal death or miscarriage, 
treatment by IVIg might be of potential interest. Unfortunately, sufficient randomized studies 
to prove the positive effect of IVIg, as has been done for previously mentioned diseases, are 
few in number (Ulcova-Gallova 2006; Smyth et al., 2010; Bayry et al., 2011). Pregnancy 
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complication and pre-eclampsia may be related to anti-phospholipid syndrome. Anti-
phospholipid and antiapolipoprotein antibodies provoke thrombosis. Spontaneous abortion 
can be prevented by IVIg dose of 1g/kg per day for 2 consecutive days every month until birth. 
As the study of Coulam and Acacio (2012) showed, IVIg treatment did not bring any benefit 
in comparison with combined therapy involving heparin and aspirin. It has been speculated 
whether or not the advantage of IVIg administration profits from a blockade of the neonatal 
IgG-Fc receptor. It may lead to the catabolism of pathologic antibodies. Anti-cardiolopin 
antibodies could be then neutralized by anti-idiotypic antibodies (Bayry et al., 2011; Coulam 
and Acacio, 2012).  
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5.1.1 Anti-sperm antibodies 
 
Sperm has a very heterogeneous antigenic content, auto-antigenic as well as iso-antigenic 
potential, and is capable to induce the production of sperm-reactive T-cells in men and 
women. Some studies suggested that it is not a single anti-sperm antibody (ASA) that 
influences fertility but is rather multiple ASA. On the other hand, a single sperm antigen is 
not able to cause infertility. There is evidence in fertile individuals reacting spontaneously to 
sperm sensitization by ASA formation, in particular 10% of fertile men and 2% of fertile 
women but fertility is not threatened. It could be concluded that not all produced ASA, in men 
and women, influence fertility potential and/or inhibit fertilization process in vitro/vivo. 
Several theories have been postulated, e.g. the cognate antigen is not necessarily involved in 
the fertilization process. Understanding of ASA formation and its mechanism could improve 
the treatment in cooperation with modern diagnosis. Then, it would be worthy to distinguish 
among individuals producing ASA without/with a fertility disorder. Furthermore, ASA are of 
interest for their contraceptive effect. The recent advance could contribute to the finding of 
antigen appropriate for such an acceptable, effective and safe vaccine. It has to reflect an 
immune response that blocks a key point in the reproductive process. Anti-sperm antibody-
mediated immune infertility provides a naturally occurring model to indicate which antigen 
would be suitable. 
The detailed mechanisms of ASA production leading to infertility are described in this 
review article. ASA are of great interest to actual research since they have been proved to be 
related to immune infertility, both male and female.  
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5.1.2 Disintegration of human sperm and characterization of its antigen 
 
The active and sensitized immune system may affect fertility. Immunological background has 
been studied in association with sperm antigens. A change in cellular immunity against sperm 
may cause the antibody-mediated rejection of semen. Our paper represents the first part of 
research that deals with the immunological properties of sperm concerning female immune 
infertility. Despite the progress in molecular genetics and proteomics, we consider sperm 
disintegration to be a key step in sperm antigen characterization. Regarding post-translational 
modifications that seem to be essential for efficient spermatozoa, it is necessary to prepare the 
protein extract in order to keep as many conformational and linear epitopes on the sperm 
antigens as possible. On the other hand, not all processes of sperm disintegration meet these 
conditions. Then, several epitopes or entire patterns might be lost or damaged. 
In this study, we focused on the mechanical and chemical disintegration in order to 
compare the detected particular sperm antigens and antigenic patterns recognized by 
immunoblotting. The sperm samples were processed by sonication, hypo-osmotic shock and 
utilization of detergents, urea and benzalkonium chloride, to process the sperm disintegration 
concerning the above mentioned conditions. The source of antibodies was the sera of female 
patients diagnosed with fertility failure. Sera were collected according to the level of sperm-
agglutinating antibodies using the Fridberg test and antibody class using indirect MAR test.  
A negative control was required as well. A serum of 10-year-old girl was apparently 
appropriate since it had been presumed that ASA might not have been present. The complex 
repertoire of sperm antigens was detected in the sperm protein extract that was prepared using 
Triton X-100. The most frequent sperm antigens had 68 and 123 kDa.  
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5.1.3 IgG, IgA and IgE reactivities to sperm antigens in infertile women 
 
Still more couples have been diagnosed with the unexplained infertility associated with 
immune infertility. Immune infertility is commonly related to anti-sperm antibody formation. 
Higher levels of IgG antibodies in women with fertility failure represent the 
immunopathological response. For better understanding, it is necessary to detect and 
characterize antigens recognized by the female immune system.  
The aim of this pilot study was to define sperm antigens implicated in unexplained 
infertility in association with IgG, IgA and IgE antibodies from sera of infertile women: IgG 
as a representative immune reaction, IgA as a potential mucosal immune response and IgE as 
a potential allergic reaction. The emphasis of experimental work was on an appropriate choice 
of the healthy individuals having normal sperm parameters. The pooled sperm extract 
represented the antigen source. We analyzed the specificity of female serum IgG, IgA and IgE 
to human sperm antigens separated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis and isoelectric focusing. IgG, IgA and IgE immunoblottings were performed 
using forty-five sera from women who were diagnosed with fertility failure. Sera of 10 
children were used as negative controls. The immunodominant sperm antigens detected by 
IgG antibodies were 68 and 123 kDa proteins, pI from 6.60 to 6.62, respectively. Concerning 
mucosal immunity the most frequently recognized sperm IgA-binding protein reached  
130 kDa and pI 6.9, 7.4, 9.5. This study did not prove an association of IgE antibodies with 
unexplained infertility in women. Collected data were used as preliminary for thorough two-
dimensional analysis and further identification. 
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5.1.4 Female serum immunoglobulins G, A, E and their immunological 
reactions to seminal fluid antigens 
 
One in five couples of reproductive age has been diagnosed with infertility. Some diagnoses 
indicate an immunological basis. Female immune infertility can be caused by semen iso-
immunization. Seminal fluid contains a range of cellular and a-cellular components that 
represent the antigenic structure evoking the response of the female immune system. Seminal 
components protecting sperm usually bind to the acrosomal region of the sperm head and are 
then carried together with sperm into the higher genital tract. Thus, seminal fluid may 
modulate the chemotactic and phagocytic response of the female reproductive tract. On the 
other hand, these seminal components might be the first targets of cytotoxic events at early 
fertilization. Moreover, the female immune system reacts by the producing of prostaglandins, 
complement inhibitors, cytokines. 
This study represented an ongoing research on female immune infertility. Actually, we 
pointed out for the first time, that to best of our knowledge, female iso-immunization is 
related to seminal fluid components as well as to sperm itself and not only to IgE-mediated 
rare allergic reaction leading to the so-called semen-hypersensitivity. The particular aim of 
our study was to prove and illustrate an association of seminal proteins with female immune 
infertility based on the female serum IgG, IgA and IgE antibodies.  
The biochemical characterization was performed by one-dimensional sodium dodecyl 
sulphate polyacrylamide gel electrophoresis and isoelectric focusing, both of which were 
followed by immunoblotting analyses. Mainly, IgG recognized the antigens with relative 
molecular masses (Mr) 95 and 183 kDa and isoelectric points ranging from 6.9 to 7.0. The 
immunodominant antigens recognized by IgA had the Mr of 35 kDa and isoelectric points 
ranging from 6.2 to 7.2. The reactivity of IgE was not confirmed within our group of patients. 
The seminal IgG- and IgA-binding patterns were analyzed immunochemically to determine 
the characteristics of possible seminal proteins associated with female immune infertility. Our 
results suggested that the anti-seminal IgG and IgA antibodies from the selected group of 
patients exhibit different specificities. We assumed that the selected infertile female patients 
may not have had an allergic built-in mechanism linked to seminal components since no IgE 
reactivity was found against proteins from the male seminal fluid. Based on our experiments, 
we proved, that immunoglobulins G as well as A were involved the female reaction of  
iso-immunization.
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5.1.5 Immunodominant semen proteins I: New patterns of sperm proteins 
related to female immune infertility 
 
Infertility affects approximately 10% of couples at reproductive age. Idiopathic causes 
indicate an immunological origin. Immune reactions may be responsible for up to 30% of 
reported cases of infertility. Semen constituents may represent potential immunogenic 
structures for women. Since vaginal and cervical tissues have an active and sensitive mucosal 
immune system, the active local immunoregulatory mechanisms in the female reproductive 
tract affect fertility. This explains the rather high percentage of infertile women in relation to 
local reactions leading to inflammation and high levels of serum anti-semen antibodies. 
Our research reflected the association of sperm proteins with iso-immunization in women 
based on the IgG-mediated reaction. The aim of our study was to identify the new patterns of 
sperm proteins recognized by serum IgG antibodies obtained from women diagnosed with 
fertility failure, and to compare them to antigens recognized by serum IgGs obtained from 
fertile women. Using a mass spectrometry-based proteomic approach, we characterized and 
determined eight sperm proteins interacting with patient IgG antibodies. HSP 70 1A/1B, HSP 
cognate 71 kDa, alpha-enolase were, for the first time, shown to be associated with female 
iso-immunization. We pointed out that sperm alpha-enolase contributes to the female immune 
infertility mediated by IgG antibodies and not only to either auto-immunization in men or the 
rare cases of semen hypersensitivity mediated by IgE in women, as has been posited so far. 
The immunodominant sperm proteins seemed to be related to antibody formation as a 
pathologic response to iso-immunization. Our results might be useful in the diagnoses of 
female immune infertility and provide potential targets for further therapeutic treatment as 
well as contribute to a better understanding of this pathologic reaction that threatens 
fertilization. 
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5.1.6 Immunodominant semen proteins II: Contribution of seminal 
proteins to female immune infertility 
 
Seminal fluid is routinely examined to evaluate semen quality and to diagnose prostate cancer. 
However, it may play a significant role in pathophysiological antibody formation, which then 
contributes to female immune infertility. Failure of natural tolerance may over stimulate  
the immune system towards SF as a complex or towards seminal proteins directly bound to 
sperm. Anti-seminal antibodies may threaten fertilization. There is a vast repertoire of 
reactions leading to the activation of inflammatory cytokines and leukocyte infiltration. 
This study represented another part of complex mosaic dealing with seminal proteins 
relevant to antibody formation in infertile women. In this report, we showed that the amount 
of IgG antibodies directed to seminal components is worth mentioning since we quantified 
the anti-seminal IgG antibodies in fertile and infertile women. Based on these results, we 
concluded that 100% of women, selected upon immune infertility criteria, express IgG 
antibodies against SF proteins. We identified the isoantigens recognized by the serum pool of 
infertile women. They seemed to be related to the pathologic immune response associated 
with female sensitization. The herein determined proteins confirmed our theory that SF 
proteins are thus involved not only in the IgE-mediated semen hypersensitivity and are not 
only a protective medium for sperm but they also represents potential immunogenic structures 
for the female immune system. Based on our results, prostate-specific antigen, prostatic acid 
phosphatase, zinc-alpha-2-glycoprotein and zinc finger protein 778 might be even considered 
as the biomarkers of such pathology within selected infertile females. 
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5.1.7 Immunodominant semen proteins III: IgG1 and IgG4 linkage in 
female immune infertility 
 
Semen-specific immunoregulatory factors as well as immunogenic agents represent  
the potential targets of the female immune system. Consequentially, inflammatory cytokines 
are produced, leukocytes infiltrate into the female genital tract and complement cascade may 
be activated. The activated immunity as reflected in sperm-reactive T-cells, anti-sperm 
antibodies, seminal protein-binding antibodies interferes with various pre/post-fertilization 
processes.  
In this study, attention was paid to the high levels of serum specific anti-seminal/sperm 
antibodies. The task consisted of the quantification of anti-seminal/sperm antibodies presented 
in the sera of infertile female patients and fertile women in order to determine  
the immunoglobulin classes and subclasses mostly involved into pathophysiological  
iso-immunization. The profiling of infertile female patients implied that antibody formation 
was not associated with allergy as IgE was not detected.  Either IgA1,2 or IgM did not 
significantly correlate with the systemic iso-immunization. Concerning our results, the 
proportionality did exist between seminal and sperm IgG1 and IgG4 antibody fractions. IgG4, 
as a minor isotype of IgGs, appeared to be mainly produced and linked to IgG1. Seminal 
antigen fraction thus seemed to be of a protein-like nature; on a contrary, sperm antigens 
rather of a polysaccharide-like character. The data shown were of value to a detailed patient 
diagnoses. Early determination of serum seminal/sperm-specific immunoglobulin G 
subclasses could contribute patient profiling and could be of interest for further  
immune-therapy. 
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Summary:  
Background: Active immune mechanism in the female reproductive tract may produce high 
levels of anti-seminal/sperm antibodies. It seems that iso-immunization is also associated with 
infertility. The aim of our study consists of the profiling of specific serum immunoglobulin 
classes and subclasses of infertile women. We focus on the distribution of serum 
seminal/sperm-specific antibodies in order to find those apparently related to  
iso-immunization.  
Methods: Immunoglobulins G1-4, A1,2, M and E were measured by ELISA in serum from 30 
infertile and 10 fertile females.  
Results: Anti-seminal/sperm IgG1 and IgG4 fractions were predominantly detected. Strikingly, 
the ratio between IgG1 and IgG2 was 3:1 in seminal specific and 2:1 in sperm specific 
antibodies. Surprisingly, IgG3 antibodies were nearly negative for both antigen fractions, 
seminal and sperm. Conclusions: Concerning our results, the proportionality does exist 
between seminal and sperm antibody fractions. Based on the poorly detectable levels of 
semen specific IgE, M, A1,2, the markers of pathologic female iso-immunization appear to be 
the serum IgG1 and IgG4. These preliminary may findings contribute to a detailed patient 
diagnosis and an improved therapy. 
 
Keywords: antibodies; ELISA; seminal fluid; sperm 
 
List of non-standard abbreviations: AP, alkaline phosphatase; F, control sera of fertile 
women; IF, sera of infertile patients; L, sperm lysate; ND, nondetectable levels; SD, standard 
deviation; SF, seminal fluid 
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IMUNODOMINANTNI SEMINALNI PROTEINI III: POVEZANOST IgG1 I IgG4 U 
IMUNOJ NEPLODNOSTI KOD ŽENA 
 
Sažetak:  
Pozadina: Aktivni imuni mehanizam ženskog reproduktivog trakta može proizvesti visok 
nivo antiseminalnih/spermalnih antitela. Čini se da je izoimunizacija takoĎe povzana sa 
neplodnošću. Cilj naše studije je karakterizacija specifičnih klasa i podklasa serumskih 
imonoglobulina kod neplodnih žena. Fokusirali smo se na distribuciju serumskih 
seminalnih/spemalnih specifičnih antitela kako bismo pronašli one povezane sa 
izoimunizacijom.  
Metode: Imunoglobulini G1-4, A1,2, M i E mereni su ELISA testovima u serumu 30 neplodih i 
10 plodnih žena.  
Rezultati: Zapažene su uglavnom anti-seminalne/spermalne IgG1 i IgG4 frakcije. Upadljivo je 
da su IgG1 i IgG2 u odnosu γ:1 u seminalnim specifičnim antitelima, dok taj odnos iznosi β:1 
u spermalno specifičnim. IznenaĎujuće, IgG3 antitela su skoro negativna za obe antigene 
frakcije, kako seminalnu tako i spermalnu.  
Zaključak: Što se tiče naših rezultata, proporcionalnost izmeĎu frakcija seminalnih i 
spermalnih antitela zaista postoje. Na osnovu slabo detektovanih nivoa seminalno-specfičnih  
IgE, M, A1,2, čini se das u glavni marker patološk izoimunizacije kod žena serumski IgG1 i 
IgG4. Ovi preliminarni nalazi mogu doprineti detaljnijoj dijagnozi i poboljšanoj terapiji. 
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Introduction 
Human semen that is defined as a complex fluid containing sperm, cellular vesicles 
and other cells and components, could immunize the female genital tract. Semen 
immunoregulatory factors as well as immunogenic agents are thus the potential targets of 
activated inflammatory cytokines, initiate leukocyte infiltration and complement cascade in 
the female genital tract. The active local immunoregulatory mechanism of the female 
reproductive tract is related to the fertility potential. Sperm is able to induce the production of 
sperm-reactive T-cells in men as well as in women. Antisperm antibodies interfere with the 
antibody-mediated infertility through various pre/post-fertilization processes (1, 2). Seminal 
antibody-binding proteins contribute to sperm metabolism, passage in the female reproductive 
tract and block an interaction with immune effectors. Seminal fluid (SF) induces pro-
inflammatory cytokines and suppresses the cell-mediated cytotoxicity (3, 4).  
In primary response to some allergens/antigens, IgE antibodies might be prevalent. 
The so-called switch into IgG and IgA antibodies is induced at the late phase of primary 
immune response and/or after the repeated exposure to the same antigen (5). After the chronic 
antigen exposure, IgG1 and IgG4 become the predominantly produced subclasses of IgG 
isotype. In addition, IgG4 is unable to activate the classical complement pathway and is then 
known as an anti-inflammatory immunoglobulin and a blocking antibody towards IgE 
antibodies. It remains still unclear whether IgG4 is a protective or rather sensitizing antibody 
(6, 7). 
In this paper, the profile of antibody-based immune response to seminal/sperm 
proteins in infertile and fertile women has been studied to document which class or subclass 
of serum immunoglobulin might be mostly involved in the immune rejection of sperm 
associated with female immune infertility. 
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Material and Methods 
Sample preparation 
Semen samples from eight normozoospermic (8) donors (aged 25-30) were treated as 
previously described (1, 4). Sperm-free SF was processed untreated; the sperm disintegration 
was processed by Triton X-100. To increase the amount of potential antigens in the protein 
extracts, the obtained individual sperm lysates (L) were pooled as well as SF. The samples 
were stored at -20 °C until assayed. All experiments were performed after obtaining informed 
written consent. 
 
Patients 
This study has been approved by the institutional ethical committees and informed 
written consent has been returned by patients. Sera were obtained from 30 women with a 
fertility disorder (patients with repeated in vitro fertilization failure, aged 29-38) and from 10 
women (control group, aged 28-37) with proven fertility (1-2 healthy children). The serum 
samples were frozen at -20 °C until assayed. 
 
Quantification of serum anti-seminal/sperm immunoglobulins 
Serum anti-seminal/sperm IgG1-4, IgA1,2, IgM, IgE and then the SF/L reactivity of 
patient and control sera were tested by ELISA. 
In the first protocol, to obtain the standard calibration curves, the micro-plates 
(MaxiSorpTM, Denmark) were coated with either mouse anti-human IgG1-4 (Calbiochem, 
United States), IgA1,2 (Abcam, United Kingdom), goat anti-human IgM (Sigma-Aldrich, 
United States) or IgE (Sigma-Aldrich, United States) in a 50 mM carbonate-bicarbonate 
buffer (9) overnight at 4 °C. The plates were saturated with 0.5% gelatine (Sigma-Aldrich, 
United States) in PBS-Tw 0.1% (4) for 2 h at room temperature. The wells were incubated 
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with the individual patient or control sera or human IgG1-4, IgA1,2, IgM, IgE (Calbiochem, 
United States) as standards of known concentration in serial dilution for 2 h at 37 °C in PBS-
Tw 0.1% and then with alkaline phosphatase (AP)-conjugated, either mouse anti-human IgG1-
4 (Calbiochem, United States), IgA1,2 (Beckman Coulter, United States), goat anti-human IgM 
or IgE (Sigma-Aldrich, United States) for 2 h at 37 °C. The AP activity was detected by p-
nitrophenyl phosphate disodium (Sigma-Aldrich, United States). Optical density was 
measured at 405 nm versus 630 nm.  
In the second protocol, to quantify the serum anti-seminal/sperm IgG1-4, IgA1,2, IgM, 
IgE, the micro-plates were coated with SF/L in a 50 mM carbonate-bicarbonate buffer 
overnight at 4 °C. The following procedure was identical to the first protocol. The anti-
seminal/sperm immunoglobulin concentrations were obtained by linear regression in 
comparison with the standard calibration curve obtained in the first protocol. 
 
Results 
Figure 1 shows the concentration of seminal/sperm-specific IgG1-4 in the individual 
sera of infertile/fertile females. In the sera of infertile women, the predominant anti-SF IgG 
subclasses were IgG1 and IgG4, reaching maximum concentration of 45 µg/ml (IgG1) and 
38 µg/ml (IgG4). In particular, anti-SF IgG1 antibodies were detected in 100% of sera tested 
with the mean of 22 µg/ml (SD 9), IgG2 in 97% with the mean of 8 µg/ml (SD 6), IgG3 in 6% 
with the mean of 0.1 µg/ml (SD 0.05), IgG4 in 90% with the mean of 12 µg/ml (SD 9). In the 
sera of infertile women, the prevalent anti-sperm IgG subclass was IgG4 ranging from 9 to 45 
µg/ml with the mean of 23 µg/ml (SD 10). Anti-sperm IgG1-4 antibodies were detected within 
all patient sera processed with the mean of 11 (SD 5, IgG1), 7.5 (SD 5, IgG2), 0.3 (SD 0.1, 
IgG3), 23 µg/ml (SD 10, IgG4). Twenty percent of control sera contained seminal-specific 
IgG1 and 30% contained seminal-specific IgG2, both of which ranged from 0.2 to 0.5 µg/ml. 
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Sperm-specific IgG1,2 were detected in 30% of control sera reaching the top value of 0.5 
µg/ml. None of the control sera had the detectable levels of anti-seminal/sperm IgG3,4. (Figure 
1 should be inserted here.) 
Figure 2 shows seminal/sperm-specific IgA1,2, IgM, IgE concentrations in the 
individual sera of infertile/fertile women. Anti-seminal/sperm IgE, IgM and IgA1 were not 
detected in the patient sera. Only 1 patient serum out of 30 contained anti-sperm IgA2 (0.18 
µg/ml). Then, 1 control serum out of 10 contained anti-seminal IgA1 (1.2 µg/ml), IgA2 (1.8 
µg/ml) and anti-sperm IgA1 (1.9 µg/ml), IgA2 (2.1 µg/ml). (Figure 2 should be inserted here.) 
 
Discussion 
We present our essential preliminary findings concerning the distribution of serum 
anti-SF/L IgG1,2,3,4, IgA1,2, IgM and IgE as a consequence of pathophysiological female  
iso-immunization.  
We show IgG1/IgG4 predominance depending on the values themselves, 2:1 in anti-
seminal specific antibodies, also valid in a reverse statement between anti-sperm IgG1 and 
IgG4 levels. The IgG1:IgG4 ratio in anti-sperm antibodies is in agreement with the working 
hypothesis of Batard et al. (5) who proved that the prolonged exposure to immunogenic 
agents such as grass pollen allergens generates IgG1 further shifting into IgG4. Then, we 
speculate that the detected antigens might be the same since the distribution of tested 
antibodies follows the similar trend of IgG1>IgG2>IgG3<<IgG4. Based on barely detectable 
IgG3 within the patient group, we assume that IgG3 does not have any protective or 
inflammatory role in female immune infertility. Among the four IgG subclasses, IgG1,3 
activate complement cascade (10). Since patients do not suffer from the inflammatory 
symptoms, we suggest that complement cascade may not be activated by IgG3 in the semen 
rejection. It has been specified (11) that the response to protein antigens is primarily mediated 
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by IgG1 and IgG3, whereas IgG2 especially and IgG4 are induced in response to 
polysaccharide antigens. Since seminal/sperm-specific IgG1 and IgG4 were inversely 
correlated, IgG1 seemed to be bind to seminal antigens of a protein character and IgG4 to 
sperm structures of an oligosaccharide nature. Whether or not serum IgG4 is a blocking or 
sensitizing antibody in infertile females remains unexplained unlike in other studies dealing 
with other pathologies (6, 7). The absence of data following patients over time prevented us to 
better understand the role of IgG4.  
Concerning male autoimmunity, IgA antibodies were proved to be associated with a 
systematic factor in male immune infertility (12). The nondetectable levels of IgA1,2 in 97% of 
female patient sera tested imply that either IgA1 or IgA2 do not correlate with systemic  
iso-immunization. However, we are able to affirm that only IgA1 is not involved in the disease 
as it predominates in the sera (13) examined in our study. Immunoglobulin M contributes to 
opsonization and is involved in the primary response to antigen exposure (14). Since the 
patient sera are not collected nor tested immediately after the sensitization, the nondetectable 
level reflects the potential secondary immune response where IgM does not play a significant 
role. However, we cannot refute that IgM is not involved either in primary or secondary 
antibody response to iso-immunization. Not a single patient was diagnosed with semen 
hypersensitivity which is in agreement with an absence of anti-seminal/sperm IgE, usually 
related to the pathophysiology of allergy (4). 
The described distribution of seminal/sperm-specific IgG1,2,3,4, IgA1,2, IgM, IgE 
indicates that immunoglobulins E, M, A1,2, G3 are not involved in pathophysiological female 
sensitization. IgG4, as the minor isotype of IgGs, appears to be mainly produced and linked to 
IgG1 in the 1:2 ratio in seminal and 2:1 in sperm specific antibodies. Seminal antigen fraction 
seems to be of a protein nature; on a contrary, sperm antigens are rather of a polysaccharide 
character. Early determination of serum seminal/sperm-specific immunoglobulin G subclasses 
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might make patient profiling more precise and complete the information for diagnosis. Anti-
seminal/sperm IgG1 and IgG4 could be of interest for further therapy targets.  
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Figure legends 
Figure 1. Quantified female serum anti-seminal/sperm IgG1,2,3,4. IF: sera of infertile patients 
(γ0), F: control sera of fertile women (10), ND: nondetectable level, ○: anti-seminal 
antibodies, : anti-sperm antibodies, bars: arithmetic means. 
 
Figure 2. Quantified female serum anti-seminal/sperm IgA1,2, IgM, IgE. IF: sera of infertile 
patients (γ0), F: control sera of fertile women (10), ND: nondetectable level, ○: anti-seminal 
antibodies, : anti-sperm antibodies. 
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5.1.8 Pre-eclampsia: a life-threatening pregnancy syndrome 
 
Pre-eclampsia is a serious pathological state affecting 5-10% of pregnant women. Its etiology 
is, so far, unknown. However, it is diagnosed in the second half of pregnancy, in particular 
after the 20th week. This life-threatening syndrome is the fatal culprit of perinatal 
morbidity/mortality, abortions or premature births.  
The origin of pre-eclampsia is explained by utero-placental ischemia, immune disorders as 
systemic inflammatory response, genetic predispositions, the malfunction structures of 
protein/lipoprotein disorders as well as by the hypothesis concerning oxygen radicals.  
The symptoms mostly correspond to the changes of blood vessels and kidneys. An inadequate 
trophoblast invasion leads to a reduced placental perfusion at the end of the first trimester, 
which is followed by endothelial dysfunction and clinical manifestation by the end of the 
second/during the third trimester.  
The monitoring of pre-eclampsia is, nowadays, a key point for women suffering from this 
disorder. The pre-eclampsia markers include blood pressure, urinal protein amount, 
insufficient cerebral perfusion, nausea, vomiting, epigastric pain, distorted vision.  
The biochemical screening includes the monitoring of malondialdehyde levels, uric acid, 
fibronectin, human chorionic gonadotropin, increase in hemoglobin and hematocrit and  
the enzyme activity of selected enzymes as the markers of oxidative stress. The complex 
monitoring and laboratory screening of risk pregnancies could contribute to a better 
understanding and be helpful for the early diagnosis of pre-eclampsia. 
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Pre-eclampsia: a Life-threatening Pregnancy Syndrom 
 
Running title: Factors in pre-eclampsia 
 
Abstract 
Pre-eclampsia is a serious pathological state affecting 5-10 % of pregnant women. Currently, it is diagnosed in 
the second half of pregnancy, particularly after the 20th week. Symptoms mostly correspond to the changes of 
blood vessels and kidneys. The severity of pre-eclampsia is proportional to symptomatic manifestations, thus the 
more symptoms present, the higher the risk is of pre-eclampsia developing. Although there are a series of studies 
dealing with pre-eclampsia pathology, the complete etiology is still unknown. In this review paper, several 
theories are presented and discussed. 
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INTRODUCTION 
Pre-eclampsia (PE) is a disorder affecting both the mother and the unborn child. It occurs only during 
pregnancy and may persist until the postpartum period. Depending on the nature of the disease, it may 
be distinguished into the mild and severe form. In some cases, early and late type of PE is indicated 
and they are discussed as separate entities. Mild PE is defined by hypertension (≥140/90 mm Hg) on 
two occasions (at least 6 h apart) without the evidence of end-organ damage, and the presence of 300 
mg of proteins in a 24 h collected urine sample but no other symptoms affecting either mother or baby. 
Severe PE is characterized by blood pressure over 160/110 mm Hg and may lead to liver/renal failure, 
disseminated intravascular coagulopathy and central nervous system abnormalities. If preeclampsia-
associated seizures are experienced, the disorder has developed into eclampsia. Premature births, 
induced by PE, are the major cause of maternal, neonatal morbidity and the increased mortality of 
newborns. The incidence rate varies from 5 to 8% of all pregnancies in developed European countries 
(Arbogast and Taylor 1996, Pre-eclampsia foundation 2013). Eclampsia and HELLP syndrome 
(hemolysis, elevated liver enzymes, low platelet count) may be an outcome of PE. This complex 
pathologic condition is most often characterized by the rise in blood pressure, which can result in 
seizures, cerebral stroke, multiple organ failure and death of the mother and/or child. Swelling, sudden 
weight gain, headache and visual disturbance are less frequent symptoms. PE occurs after the 20th 
week of pregnancy and is therefore not diagnosed until the second half of pregnancy based on 
emerging clinical symptoms. In rare cases, it may occur before the 20th week. Although the etiology is 
unclear, several PE risk factors are known. The most common manifestations include hypertension, 
edema and proteinuria. However, the higher permeability of placenta is also associated with PE. The 
higher permeability of oxygen reactive forms through the placenta may lead to the development of 
oxidative stress (OS) (Arnostova et al. 2007, Escudero and Sobrevia 2008, Pre-eclampsia foundation 
2013). Several theories have been suggested to explain the origin of PE: the hypothesis of 
uteroplacental ischemia (changes in the biology of placenta), immune disorders (systemic 
inflammatory response), genetic predispositions, malfunction structures of protein/lipoprotein 
disorders, and the hypothesis of oxygen radicals (Anthony and Johanson 1996). The hypothesis of 
uteroplacental ischemia is based on the expression of cytotrophoblastic adhesive molecules. It is 
suggested that the reduced penetration of substances through placenta leads to fetal damage and the 
release of toxic substances with some regulatory factors. A common pathologic finding is a placenta 
with multiple surface infarcts (Mechurova 2002). The current theory concerning the pathophysiology 
of preeclampsia discusses a lack of trophoblast invasion into the wall of the spiral arteries. It is linked 
to the hypothesis of systemic inflammatory response supported by the fact that the fetoplacental unit 
contains paternal antigens that are capable of slowing down the trophoblast invasion. The following 
consequence consists of the hepatic expression of human leucocyte antigen G (HLA-G) that may 
inhibit trophoblast invasion in uterine smooth muscle. Subsequently, the activated leukocytes release 
an elastase and attack an endothelium (Mechurova 2002, Stara 2012). Genetic hypothesis is based on 
the genetic predisposition of daughters whose mothers have a verifiable PE history. In this case, the 
risk of disease increases up to 22%, for sisters up to 39% (Mechurova 2002). The PE patients have a 
higher concentration of triglyceride and the lipoproteins of very low density (VLDL) in the plasma. 
VLDL hypothesis derives from the endothelial lining of the vascular damage effect of VLDL. The 
most discussed theory is that of OS. The balance between the oxygen radicals and antioxidants is 
disrupted during PE development. Natural antioxidant ability is unfortunately reduced, which may 
lead to placental OS. This hypothesis is supported by the fact that the placenta in PE patients exhibits 
discontinuous perfusion due to the reduced pathological trophoblast invasion into the maternal 
vascular system. The above mentioned OS is considered as a significant consequence causing the 
reduced placental permeability (Borzychowski et al. 2006). 
 
PATHOLOGY OF PRE-ECLAMPSIA 
Nowadays, the PE syndrome is considered as a two-stage disease. The first stage is defined by the 
reduced placental permeability (specific proteins, placental „debris‟) associated with abnormal 
implantation and fetal placental release into the maternal circulation. The malfunction of placenta may, 
in some cases, induce hypertension, renal impairment, proteinuria, the damage of other organs and the 
HELLP syndrome. The second stage is the maternal reaction to this condition. It is characterized by 
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inflammation and the endothelial dysfunction of parental cells (Redman and Sargent 2000). One of the 
fundamental pathophysiological changes is the so-called firm connection of fetal and maternal 
placenta. Pathological examination of placentas has documented the placental infarction, narrowing of 
arteries and blood vessels, fibrin deposition and venous thrombosis. Placental ischemia induces 
hypertension, proteinuria, is also associated with the deposition of fibrous material in the glomerular 
tubules - called glomerular endoteliosis (Baumwell and Karumanchi 2007). The promising recent 
research deals with proteins that are produced by placenta and inhibit angiogenesis. Vascular 
endothelial growth factor (VEGF) and placental growth factor (PIGF) are pro-angiogenic factors that 
are involved in trophoblast proliferation (Grill et al. 2009). The growth factors and their receptors 
originate in the placenta. Placental cells also secrete the soluble isoform receptor (sFlt-1), which is 
generated through an alternative mRNA splicing. Soluble Flt-1 isoform has a role as an anti-
angiogenic factor. It neutralizes the effect of PIGF and VEFG. The over-expression of sFlt-1 is 
associated with placental ischemia and hypoxia (Clark et al. 1998). Cooper et al. (1996) reported that 
VEGF and PIGF concentration are lower in the second trimester in women with late PE in comparison 
with physiological pregnancies. This fact is most significant in patients with severe PE, where VEGF 
and PIGF amount is reduced in comparison with women with mild PE (St-Jacques et al. 1994). 
Maternal immune disorders play an important role in the pathophysiology of PE. Trophoblasts contain 
a wide range of immunogenic agents, such as HLA-G. This glycoprotein is responsible for the low 
trophoblast immunogenicity along with the high resistance to the maternal immune reaction. The 
presence of trophoblast with an insufficient HLA-G expression can activate the incompatible decidual 
immune cells in the uterine cavity (Matthiesen et al. 2005). The placental vascular wall is an integrated 
organ, composed of endothelial cells, smooth muscles and fibroblasts. Endothelial cells contain the 
surface receptors for thrombin, clotting factors, angiotensin II, and many more. Cytokines (e.g. 
interferon-gamma) and various types of reactive oxygen species mediate an endothelial dysfunction. 
Clinical symptoms usually appear after the 20th week of pregnancy. Endothelial dysfunction may 
result in the increased permeability of endothelial cells, activation of platelets and the coagulation 
cascade, shifting the balance of vasoactive mediators and thus favoring vasoconstriction and the 
development of OS (Davidge 1998). 
 
CLINICAL MANIFESTATION OF PRE-ECLAMPSIA 
The clinical manifestation varies since PE is associated with several risk factors (obesity, molar 
pregnancy, hypercoagulation, formation of clots, diabetes mellitus). It is reported that the prevalence 
of PE increases up to 66% if there is already an existing chronic kidney disease (Baumwell and 
Karumanchi 2007). It was found that male seminal plasma antigens, expressed on trophoblasts, reduce 
the risk of PE. The major clinical manifestation includes hypertension, proteinuria, edema, 
hyperuricemia and HELLP syndrome. Blood pressure is a function of peripheral vascular resistance 
and cardiac output. According to the World Health Organization (WHO), hypertension is considered 
as a blood pressure of 140/90 mmHg or higher at two separate measurements within 6 h (Hajek 1999). 
Proteinuria means the increased amount of total proteins in the urine. Glomerular membrane damage 
and reduced protein absorption in the back tubules cause an increase of up to 300 mg in 24 h (Brown 
et al. 2001). Swelling is caused by the increased protein loss or the inadequate intake of fats and sugars. 
In the advanced stage of pregnancy, it may be caused by obstruction due to enlarged veins in the 
uterus (Felfernig-Boehm et al. 2000). Hyperuricemia is defined as the increased level of uric acid in 
the blood. If the level is higher than γβ0 μmol/l, it becomes one of the primary PE indicators. The 
most significant cause of hyperuricemia is the insufficient feedback resorption of uric acid in renal 
tubules (Cai et al. 2009). HELLP syndrome differs from PE by hemolysis, the increased activity of 
liver enzymes and decreased level of platelets. HELLP is diagnosed in 20% of severe PE with the so-
called thrombotic microangiopathy, which is defined as a syndrome involving the occurrence of clots 
in the veins, acute hemolytic anemia and thrombocytopenia (Felfernig-Boehm et al. 2000, Stara 2012). 
 
CLINICAL SCREENING FOR PRE-ECLAMPSIA 
The PE markers include increased blood pressure, elevated or decreased protein in the urine, 
insufficient cerebral perfusion (headache, dizziness, tremor), nausea, vomiting, epigastric pain, 
distorted/double vision. Nowadays, the laboratory screening includes the monitoring of 
malondialdehyde levels, uric acid, fibronectin, human chorionic gonadotropin (hCG), increase in 
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hemoglobin and hematocrit and the enzyme activity of selected enzymes (aspartate aminotransferase, 
alanine aminotransferase and lactate dehydrogenase). Malondialdehyde, which is a lipid peroxidation 
product, can be used as a new PE marker (Hajek 1999). Purine level is dependent on the influence of 
oxygen radicals. Although the released fibronectin from damaged vascular endothelial cells could 
theoretically contribute to PE prediction, this marker may easily provide false-positive results 
(Friedman and Schiff 1995). 
 
ASSOCIATION OF OXIDATIVE STRESS AND PRE-ECLAMPSIA 
Oxidative stress is an imbalance between the free radicals and reactive oxygen species and their 
elimination by antioxidants. OS represents a disproportion between the oxidants and the antioxidants. 
This misbalance leads to cell damage that may influence the entire body (Durackova 2010). Reactive 
oxygen species (ROS) are described as the molecules of independent existence. Free radicals, with 
their unpaired electron, exhibit a high chemical reactivity towards other organic molecules. The main 
source of free radicals is the mitochondrial respiratory chain. It is known that 1-4% of oxygen is 
converted to superoxide and hydrogen peroxide during oxidative phosphorylation. Another source of 
free radicals is biotransformation process in the endoplasmic reticulum. The exogenous factors, which 
significantly increase the production of free radicals, are: UV radiation, smoking, industrial pollution, 
pesticides, some pharmaceuticals and many organic solvents. ROS can cause intracellular reactions 
with lipids, DNA and proteins. These interactions can lead to the loss of cell permeability/genome 
stability and also other cellular functions (Cadenas and Sies 1998). PE causes hypoperfusion, placental 
ischemia and hypoxia and also reduces placental permeability so that reactive oxygen compounds are 
intensively produced. A reduced placenta can release various mediators such as the hCG hormone, 
cytokines, reactive oxygen and nitrogen species (nitrous oxide, hydrogen peroxide, superoxide anion). 
These mediators are detected when endothelial dysfunction occurs (Llurba et al. 2001). The 
throughput of reactive oxygen increases along PE developing during pregnancy. This fact may lead to 
OS (Dennery 2010). The most important enzymatic oxidants are catalase, superoxide dismutase, 
glutathione-S-transferase, glutathione reductase and glutathione peroxidase (Kaur et al. 2008). 
 
CONCLUSIONS 
Albeit the vast advances in research and knowledge of PE during recent times, the basic research is 
unfortunately still lacking behind. This life-threatening syndrome is the fatal culprit of perinatal 
morbidity/mortality, abortions or premature births. It is suggested that an inadequate trophoblast 
invasion leads to a reduced placental perfusion at the end of the first trimester, which is followed by 
endothelial dysfunction and clinical manifestation by the end of the second/during the third trimester. 
Despite the therapeutical progress, the diagnosis is still very complicated. Currently, the diagnosis of 
PE is based on clinical symptoms that are noticeable at the end of the second trimester. Therefore, 
great attention is paid on the biochemical actions associated with the development of PE. The 
monitoring of biochemical markers could contribute to a better understanding and be helpful for early 
diagnosis. Whereas the main causes of PE are still unknown, the current research of biochemical 
processes associated with PE requires much more attention and financial support. 
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6 FUTURE ASPECTS 
 
6.1 Design of a miniaturized diagnostic tool 
 
The aim of designing a diagnostic tool consists of the differentiation between sperm and the 
seminal sensitization of infertile women in order to make medical diagnoses more 
comprehensive, and to hasten the therapeutic intervention. Such expertise has to be easily and 
rapidly performed to provide an answer, e.g during the consultation with a reproductive 
immunologist. These requirements may be fulfilled by, for instance, lateral flow 
immunoassay-based device (LFIA, Fig. 12, 13) acting on the immunochemical detection of 
specific antibodies. LFIA is a widely used technology to detect pathogens  
(Karakus and Salih, 2013), toxins (Anfossi et al., 2013), contaminants (Maiolini et al., 2014) 
and is a reliable and important assistant for diagnostic purposes, such as pregnancy test  
(Posthuma-Trumpie et al., 2009). However, to the best of our knowledge, our aim is the first 
report concerning the design of a colloidal nanometer-sized-particle-based test for the multi-
analyte detection (seminal and/or sperm sensitivity of infertile women). In general, the LFIA-
based test is simply and fast performed by medical or research specialists as well as any 
person without professional or specialized training. It also requires a very low amount of 
testing analyte, no reagent preparation and no specialized equipment, all of which contribute 
to a low-cost alternative to expensive experimental measurements (Kolosova et al., 2007). 
The choice of a membrane-based format is in favor of a qualitative one-step test with visually 
interpreted results. Based on the knowledge, experience and results obtained during our 
experimental procedures, the cyanogen bromide (CNBr)-activated nitrocellulose (NC) 
membrane (Demeulemester et al., 1987) seems to be the most appropriate surface layer. As 
the membrane is thin and fragile, it has to be attached to a solid support. The intended 
miniaturized diagnosis device would consist of two main parts to test the seminal as well as 
sperm sensitivity of female patients to immunodominant antigens. Each testing part would 
involve three testing wells, the first one to detect patient reaction, the second one as a positive 
control acting as a reference for the intensity of reaction related to the patient tested and to 
allow quantitative evaluation, and the third one as a control zone acting as a reference to show 
whether the reaction works properly or not. Briefly, the patient profiling procedure would 
consist of the application of a blood drop directly on the deposit place, into the input window 
(the first well). The CNBr-activated NC sheet serving as a capillary bed would easily 
transport the applied fluids. When soaked, blood led by a thin capillary would migrate to a 
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filter. Serum or plasma, depending on the presence or absence of coagulating compound on 
the filter itself, would migrate. While passing through an antibody mobile tracer, the analytes 
(present in serum or plasma) would bind to conjugate (IgG) coupled with nanoparticles. The 
antibody mobile tracer would contain purified immunoglobulins against immobilized seminal 
and sperm antigens, coupled with nanoparticles. The complexes of sample analytes and 
conjugates would migrate to the immobilized seminal and sperm antigen strips. If the 
complexes bind to the so-called strips, the strip-area changes color. Optical detection is based 
on gold nanoparticles. The migrating fluids then enter the wick, acting as a waste recipient. 
According to the positive control zone, it would be possible to compare the intensity of 
patient reaction, and according to the third window position, to confirm whether or not the 
reaction works properly. The LFIA set-up test may take a few minutes to be developed 
depending on the sensitivity (Posthuma-Trumpie et al., 2009). The detection thresholds and 
cut-off levels have to be precisely determined. Attention has to be paid to the fact that the 
device has been designed based on the results obtained and corresponding to the human 
subject selected for this study. Eight male healthy normozoospermic individuals (the average 
age of the voluntary donors was 27) and female infertile patients diagnosed with repeated 
unsuccessful in vitro fertilization (the average age of the women was 35) were selected. As 
we assume that described and proposed protein markers related to female iso-immunization 
may have more than one epitope, the sandwich format is applicable. In this case, the optically 
observed response is supposed to be proportional to the amount of analytes in the applied 
sample. 
 
 
6.2 Immuno-Intervention in female immune infertility 
 
Therapeutic regimens have, most of the time, been developed to counter autoimmune defects.  
Female fertility disorders have been associated with a failure of natural tolerance to male 
semen, resulting in a cascade of immune reactions, the activation of the female immune 
system and sperm rejection. Treatments using intravenous immunoglobulins may act on the 
tolerance level of the female immune system. IVIg may modify inflammatory response, 
interfere with natural killer cell cytotoxicity, the proportion of peripheral blood cells, Th1:Th2 
ratio and with Treg cells. All these facets may interact to achieve a successful pregnancy. 
However, the existing studies of extensive IVIg effect in patients with pregnancy failure have 
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not reached statistical significance. As immuno-intervention is only the theoretical aspect of 
this thesis, IVIg benefit is a subject of debate.  
 
 
Fig. 12 External view of a colloidal gold-based lateral flow immunoassay for diagnostic purposes 
concerning female iso-immunization caused by seminal and/or sperm antigens. SF: seminal 
fluid, L: sperm lysate, T: testing zone, P: positive control zone, C: control zone of test 
function, (1): unused device, (2): device used to reveal the patient sensitivity to seminal and 
sperm antigens. 
 
 
 
Fig. 13 Detailed view of internal composition of testing zone in a miniaturized diagnostic device. 
CNBr-activated: cyanogen bromide (CNBr)-activated, NC: nitrocellulose. 
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7 DISCUSSION 
 
Immune infertility, in terms of reproductive failure, has become a serious and frequent 
problem involving a significant number of couples. Immunological aspects play an important 
role during many stages of reproduction. 
 
 
7.1 Antibody recognition 
 
Immunoglobulin diversity becomes apparent in certain stages of B-cell development. During 
the primary response to antigen exposure, IgM and IgD are co-produced. The process of IgM 
and IgD expression is entirely antigen dependent. A reaction associated with hypersensitivity 
and parasite infection provokes generation of IgE antibodies. Although IgE is produced 
mainly in allergic states and in response to parasite infections, it is the serum immunoglobulin 
of lowest concentration in healthy individuals. In addition, it has the shortest half-life (few 
days). Within the secondary immune response, the so-called class switch recombination is 
processed and IgG antibodies become prevalent. IgG is the predominant isotype present in 
body except mucosae, wherein IgA predominates. IgG also has the longest serum half-life 
(around 20 days) and exists in four subclasses that differ in specificity, function and 
concentration. The common distribution is as follows: IgG1>IgG2>IgG3>IgG4. Considering 
the totality of all the IgGs, IgG1 comprises in approximately 60%, IgG2 accounts for 25%, 
IgG3 for 10% and IgG4 for 5% (Svensson et al., 2013). Only IgG1 and IgG3 can effectively 
activate complement, as the activation ability of IgG2 is too low and IgG4 completely fails to 
fix complement. In general, the distribution of serum antibodies follows the IgG>IgA>IgM 
rank order in healthy individuals regardless of gender and age (Schroeder and Cavacini, 2010; 
Tamayo et al., 2012; Jefferis, 2012).  
Changes in immunoglobulin isotype levels are related to the type of disease. 
Preponderance of certain isotype subclasses reflects ongoing immunological processes and is 
specific to certain pathologies. Increased concentration of IgEs is correlated with allergies and 
to responses to some parasites. In the case of specific immunotherapy, prolonged exposure to 
antigenic stimuli induces increase levels of specific IgG4 in allergic patients. In some 
autoimmune disorders, for instance acute or chronic bullous pemphigoid, specific IgG1 and 
IgG4 were revealed as dominant. Patients suffering from this skin disease are diagnosed with a 
deficiency of IgG3 (Dopp et al., 2000). Other autoimmune pathologies, for instance 
105 
 
myasthenia gravis, are specific IgG1 and IgG3-mediated (Liu et al., 2011). With regards to our 
results, the anti-seminal/sperm antibody distribution of infertile female patients follows the 
IgG1>IgG2>IgG3 ratio (Brazdova et al., 2013a; Brazdova et al., submitted 2014b). Suprisingly, 
specific IgG4 was detected as the apparent predominant subclass and appeared to be linked to 
specific IgG1. The sort of relationship also exists does exist also between specific IgG1 and 
IgG2. Unlike other studies (Yamada et al., 1989; Dopp et al., 2000), our patients reflected the 
elevated levels of specific IgG1, IgG2 and IgG4. The distribution did not vary within the 
patients selected. As other diseases are associated only with the increased levels of some IgG 
subclasses, e.g. cystic fibrosis and chronic Pseudomonas aeruginosa with specific IgG2 and 
IgG3, female immune infertility, and in particular the repeated IVF failure, may be related to 
autoimmune phenomenona and notably to IgG1 and IgG4-mediated reactions. IgG subclasses 
may thus indicate specific immune responses and represent potential targets of immuno-
therapy. 
 
 
7.2  Protein markers 
 
Iso-immunization is related to immune infertility and is caused by semen protein/s. 
Identification of immune-dominant semen proteins or their entire repertoires is the key point 
to a better understanding of female sensitivity to male semen. Provoked antibody formation 
may be associated with individual proteins. Such markers are needed to provide information 
about the stage of disease in the prior to therapy. The goal of this study is to find clear and 
reliable markers of female iso-immunization, i.e. specific proteins to which the immune 
system reacts by inducing high levels of serum antibodies preventing the fertilization. The 
plan consisted of utilization of obtained results as reference points to design a diagnostic 
device. This device should, in a timely and quickly manner, distinguish between seminal fluid 
and sperm sensitivity of infertile female patients. Such markers have to be specific enough to 
avoid incorrect analysis through recognition by natural antibodies present in sera of fertile 
women.  
In men, auto-immunity to sperm has already been reported to heat shock 70 kDa protein, 
heat shock related 70 kDa protein 2, disulfide isomerase ER60, inactive form of caspase-3, 
component β and ξ chain subunits of the proteasome and alpha-enolase. These proteins were 
pointed out as indicators of impaired sperm function and male infertility associated with ASA 
(Bohring et al., 2001; Bohring and Krause, 2003; Domagala and Kurpisz, 2004). Different 
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protocols to process sperm disintegration provide different protein mixtures, thus different 
antigens could be determined. To avoid exclusion of membrane or cytoplasmic antigens, it 
was decided to follow the sample preparation by which most of epitopes are kept  
(Brazdova et al., 2011). Concerning iso-immunization, the female immune system recognizes 
a set of proteins that differs from those interacting with male antibodies as well as another set 
of proteins that are in common (Brazdova et al., 2013b). Sperm heat shock 70 kDa protein, 
heat shock related 70 kDa protein 2 and alpha-enolase are recognized as auto- as well as iso-
antigens. This puts them in a class of universal markers linked to antibody-related infertility. 
Alpha-enolase is, in addition, an IgE-binding sperm protein as previously reported  
(Lopez-Alemany et al., 2003). This fact supports the previous hypothesis of universal markers. 
Another protein, disulfide isomerase, participates in the rearrangement of sperm proteins and 
in the composition of the final antigen exposure (Bronson, 2011). Type ER60 is recognized 
by male serum IgG auto-antibodies (Bohring et al., 2001; Bohring and Krause, 2003) and type 
A3 by female serum IgG iso-antibodies (Brazdova et al., 2013b). The identification of this 
enzyme proves its general significance in immune infertility. 
Human seminal fluid is a concept often discussed in terms of prostate cancer and allergic 
reactions. In the background of these two distinct immune reactions, PSA plays a key role as 
corresponding marker. In addition, PSA and PAP are used to monitor the pathological 
spermiogram and the progression of prostate cancer (Jones, 1991; Weidinger et al., 2008). 
PSA and PAP were shown in this study to contribute to female immune infertility. They may 
indicate the activated humoral immunity of infertile women as they were recognized as IgG-
binding immuno-dominant proteins in the presented results. Some seminal components may 
complex with sperm proteins that enables the effective recognition by female immune system 
followed by antibody formation. As it has been shown (Brazdova et al., 2013a), some sperm 
proteins are recognized by female serum antibodies only in complex with those of seminal 
fluid origin. ZAG has been shown to have this ability (Brazdova et al., 2013a). Based on the 
obtained results, heat shock protein 70 kDa, heat shock related 70 kDa protein 2, disulfide 
isomerase, alpha-enolase, zinc alpha-2-glycoprotein, prostate-specific antigen and prostatic 
acid phosphatase should constitute a comprehensive list of markers that will improve the 
actual diagnoses. 
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7.3 Immunoassay to screen female semen sensitivity  
 
An immunoassay is defined as a laboratory technique based on the principle of specific 
binding between an antigen and its homologous antibody in order to identify and quantify the 
specific antigens or antibodies in a sample. Immunoassays rely on the inherent ability of a 
selected antibody to bind to the specific structure of an antigen, and thus exploit the ability to 
form the immuno-complex (Yetisen et al., 2013).  
For decades, immunoassays have been ubiquitous in research laboratories and have 
progressed studies of biological systems by tracking different analytes. For over 40 years, 
these tests have been used for biomedical purposes to improve the state of diagnoses by 
making them more accurate. It has enhanced the possibility of earlier diagnoses and decreased 
the severity of illness by identifying and assessing the progression of disease. It strengthened 
confidence in the choice of therapeutic approach. Nowadays, immunoassay is a routine test. 
In the agro-food industry, immunoassays are used to detect contaminants. They also 
contribute to monitor specific molecules used during product processing in quality control. 
Many home pregnancy tests are actually the immunoassays detecting human chorionic 
gonadotropin as the pregnancy marker. Other examples of clinical immunoassays include 
tests that measure levels of insulin to assess hypoglycemia or prostate-specific antigen to 
detect prostate cancer (Butler et al., 2001; Chatterjee et al., 2008). 
Exclusively for every test, it is necessary to consider the type of assay with an impact on 
either qualitative or semi-quantitative approach related to basic principles. In addition, 
characteristics such as the potential limitation and aspects such as membrane material, 
material of the sample and absorbent pad, type and size of the label, recognition element, 
position of the test line, optimization and the last but not the least the concurrency of 
automated formats must be considered. Furthermore, the type of immuno-pathologic reactions 
(type I-IV) related to the disease has to be considered as well (Posthuma-Trumpie et al., 2009). 
As infertility has been becoming a civilization disease, the progress of medical and 
research attempts is enormous. Immune infertility is commonly associated with antibody 
production against male semen. Women suffering from this fertility disorder have to often 
undergo a long-term treatment. To make the patient information more comprehensive and to 
provide a complete diagnosis, the miniaturized device has become of a research interest. 
Infertile female patient screening for the sensitivity to sperm and/or seminal antigens might 
make the therapy simplified. Several choices were taken into account: enzyme-linked 
immunosorbent assay, memory lymphocyte immuno-stimulation assay, lateral flow test, 
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magnetic immunoassay, radioimmunoassay, blotting analyses and microfluidic device. LFIA 
may be an appropriate test to be performed within a few minutes, even at bed site, requiring 
only basic equipment. The results can be given in qualitative and semi-quantitative forms. 
This type of test is intended for primary individual screening to evaluate the presence or 
absence of female serum antibodies against immuno-dominant semen proteins, seminal as 
well as sperm. On the other hand, it could be used as a reference to monitor treatment 
progress of ongoing antibody generation as this test would provide semi-quantitative results 
as well. In addition, only limited sample pre-treatment is needed.  
 
 
7.4 Immuno-Intervention strategies 
 
The development of drugs that would intervene in the immune system is, at present, of 
scientific interest. Plenty of specific and unspecific immuno-stimulatory strategies have been 
applied. Numerous approaches agree on whole cell vaccines, peptide vaccines and dendritic 
cell-based immunotherapy, all of which proved their safety based on quality control and 
clinical trials. These mandatory issues allow dividing the patients into sub-groups depending 
on their immune response. The question of T- and B-cell antigen assessment is a novel subject 
for clinical immunotherapy (Geissler and Weth, 2002). 
The aim of vaccination, either by a whole cell or peptide, is to induce protective immunity. 
The crucial step consists of the identification of the antigen inducing a common reaction in all 
individuals, then in the prediction of immune response and protective mechanism. Antigen 
has to be chosen to fulfil the requirement to bind to at least one allele of MHC in every human 
individual. The serious risk is related to T- and B-cell antigen selection that may elicit an 
inappropriate immune response in some subjects and fail to induce protective immune 
response in all subjects. Therapeutic intervention may also regulate signaling pathways 
concerning T- and B-cell expansion. Furthermore, regulation can operate on the ligand-
receptor binding to inhibit T-cell response or it can act on the signal transduction 
(Lanzavecchia, 1993). In general, T-cells are the targets of therapeutic immuno-intervention. 
Regarding high levels of antibodies preventing early steps of fertilization, this therapeutic 
immuno-approach might be potentially subjected to immuno-contraception research. However, 
the precise effects related to immunological mediator, risks and efficacy have to be taken into 
account in the design of such a vaccine.  
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Therapeutic approaches may depend on the polyvalent character of natural antibodies. 
Natural antibodies are effective molecules of the immune system. They serve as the so-called 
first line barier to the infection. The effect of intravenous immunoglobulins is associated with 
natural antibodies. IVIg is a commercially produced mixture of blood immunoglobulins 
obtained from at least 1000 healthy donors. IgG predominates in IVIg. IVIg is suggested to 
display the entire antibody repertoire, notably the panorama of specificities. Despite the fact 
that monomeric immunoglobulins predominate, dimers are present as well. The mechanisms 
of action are plenty. It is mainly used as a treatment in three major disease categories, (1) 
primary and secondary immune deficiencies, (2) autoimmune diseases and (3) acute 
infections. The efficiency of the therapy is controversial as there is evidence of side effects 
(Nimmerjahn and Ravetch, 2005; Seite et al., 2008; Kaveri, 2012). IVIg is also used as a 
treatment for unexplained recurring miscarriages. Regarding immune infertility, women 
having local immune reaction might not significantly benefit from IVIg as (1) IVIg is given as 
an infusion made primarily of IgG antibodies mainly and the immunity of the genital tract is 
associated with IgA antibodies, thus (2) the beneficial effect is related to IVIg biological 
activity and lifetime of at least 21 days (Yamada et al., 2012). In this case, continuous iso-
immunization would maintain the production of specific anti-seminal and anti-sperm 
antibodies. On the other hand, IVIg may induce a starting effect in cellular processes resulting 
in the normalization of anti-seminal as well as anti-sperm pathologic reaction. This 
therapeutic immuno-approach may act on idiotype regulatory network and also benefits from 
Treg immuno-suppressive activity or other still unknown immunoregulatory circuits, IVIg 
could be a valuable immuno-tool to restore physiological, non-pathologic, female reaction to 
male semen. 
Regarding female IgE-associated reaction to male semen, IVIg might act as blocking 
antibodies toward generated IgE. However, anaphylactic shock provoked by seminal fluid 
could become severe as one of the potential IVIg side effects. Given that the affected women 
would be in addition IgA deficient patients who can, by definition, produce IgG antibodies, 
these patients would more likely produce IgG against the IVIg (Orbach et al., 2005;  
Katz et al., 2007). Nevertheless, it has not been shown, so far, that IgE-mediated allergic 
reaction of women to seminal fluid is related to infertility. In this case, the administration of 
IVIg would not be of effective value.  
On the other hand, as this work is focused on the female patient diagnosed with repeated 
IVF failure, IVIg could be a useful treatment in some cases of women undergoing repeated 
IVF loss. IVF success depends on endometrial thickness, embryo quality and number 
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implanted, maternal age and, of course, the reactivity of maternal immune system. Most of the 
time, IVIg is applied in combination with Humira as a TNF inhibiting anti-inflammatory drug, 
heparin and aspirin (Coulam and Acacio, 2012; Li et al., 2013). Studies that empirically 
introduced IVIg differ in duration, up to 7, 20, 28 weeks or even during the entire pregnancy. 
The precise mechanism of IVIg effect has not been clarified in the selected female patients, 
yet. IVIg therapy may thus depend on a synergic effect with the immuno-modulatory 
components of individual patients. This immuno-intervention may also play a role in the 
neutralization of pathologic antibodies and circulating auto-antibodies by anti-idiotypic 
network (Haller et al., 2008; Jerzak et al., 2010; Coulam and Acacio, 2012). The positive 
effect is not negligible. Unfortunately, the various ages of patients followed in numerous 
studies, diversity of statistical tests to evaluate patient sub-groups and various durations of 
IVIg administration prevent strong conclusion of the beneficial effect of IVIg in patient with 
previous IVF failure. Promising results and clear evidence remain to be confirmed as it has 
already been done in the case of autoimmune diseases. By all odds, IVIg immuno-intervention 
has been definitely highlightedfor its positive aspect. 
  
111 
 
8 CONCLUSION 
 
1. The submitted work deals with female immune infertility with respect to iso-
immunization and the levels of anti-seminal and anti-sperm antibodies from sera of 
women with fertility disorders. For this purpose, ELISA, one- and two-dimensional 
SDS-PAGE followed by mass spectrometry were chosen to determine the 
immunological properties of sperm and seminal plasma antigens involved in such 
pathologies. 
 
2. The sera of infertile female patients were donated in cooperation with the Counseling 
and Laboratory for Reproductive Immunology - Genetics Pilsen, Czech Republic given 
the criteria of the positive Friberg spermagglution test and indirect mixed antiglobulin 
reaction test.  Sera were obtained from 30 women with a fertility disorder (patients with 
repeated in vitro fertilization failure, aged 29-38) and from 10 fertile women (control 
group, aged 28-37) with proven fertility (1-2 healthy children). Normozoospermic 
semen samples were obtained from 8 volontary, healthy donors (aged 25-30). 
 
3. The design of the protocol to prepare a protein sample was based on our studies 
published in this field. These methods used were as mild as possible in order to keep a 
maximum of epitopes, both of seminal and sperm origin, in their native conformations. 
To enrich protein sample and to increase the amount of potential antigens, individually 
prepared samples were pooled (Brazdova et al., 2011). 
 
4. Quantification of seminal- and sperm-specific antibodies present in the sera of infertile 
women was performed by ELISA. The results were compared to a control group of 
fertile women with poorly detectable serum seminal- and sperm-specific antibodies. 
 
5. Thereafter, it was shown that the distribution of serum specific anti-seminal/sperm 
immunoglobulin G corresponds to the following trend: IgG1>IgG2>IgG3 including high 
levels of IgG4, all of which were observed in all 30 patient sera while the levels in sera 
of fertile women were barely detectable. Predominantly detected fractions were anti-
seminal/sperm IgG1 and IgG4. Surprisingly, the levels of anti-seminal and anti-sperm 
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antibodies differed in IgG2 fractions. In addition, IgG3 antibodies were nearly negative 
for both antigen fractions, seminal and sperm (Brazdova et al., submitted 2014b). 
 
6. The output of the presented thesis might be of medical interest. Early determination of 
specific antibodies, and specifically those of anti-seminal and/or anti-sperm character, 
would provide detailed information related to the pathology of infertile women.   
 
7. One-dimensional seminal and sperm protein mapping was run simultaneously by SDS-
PAGE and IEF, both of which were followed by immunoblotting. IgG and IgA 
recognized seminal as well as sperm antigens. However, IgG and IgA specificity differs. 
IgA-binding seminal proteins are predominantly of low molecular mass and pI ranging 
from acidic to neutral while IgG-binding seminal proteins are of high molecular mass 
and pI neutral. On the other hand, IgA-binding sperm proteins are of high molecular 
mass and of pI ranging from neutral to basic. IgG-binding sperm proteins are a 
heterogeneous group with molecular mass ranging from 60 to 180 kDa and pI neutral 
(Brazdova et al., 2012a, b).  
 
8. The following essential step consisted of two-dimensional protein mapping. Immune 
infertility is known to be associated with sperm heat shock proteins. The known group 
of iso-antigens was extended by heat shock protein 70 1A/1B and heat shock cognate 
protein 71 kDa, which were firstly reported as related to female iso-immunization 
(Brazdova et al., 2013b). In addition, one protein, alpha-enolase, was detected as auto- 
as well as iso-antigen (Domagala and Kurpisz, 2004; Brazdova et al., 2013b). 
 
9. Strikingly, seminal proteins play a notable role in female immune infertility. So far, 
seminal fluid has been associated with the IgE-mediated semen hypersensitivity. Such 
an immune response has never been found in the presented work. Based on two-
dimensional characterization followed by mass spectrometry identification, a prostate-
specific antigen, prostatic acid phosphatase and zinc finger protein 778, were 
determined as immunodominant among IgG-binding seminal proteins recognized by the 
sera of infertile women (Brazdova et al., 2013a).  
 
10. Three-dimensional evaluation (integrated density) of two-dimensinal electrophoresis 
and immunoblotting confirmed the above mentioned proteins to be immunodominant 
and associated with iso-immunization (Brazdova et al., 2013a). 
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11. Potential innovation of presented results consists of their power to be used to conduct 
the specific immuno assay. Morover, wider applications of such immuno assay would 
be highly valuable to resource/equipment-poor consulting rooms. Lateral flow 
immunoassay seems to be the best choice used as a point of care test for primary 
screening as well as follow-up. 
 
12. Immunotherapy inherently belongs to infertility treatment. The non-invasive approach 
afforded by IVIg may be a valuable treatment of female infertility. IVIg has already 
been widely used therapeutic intervention in immune-mediated disorders as it acts on 
various immune components. Immuno-modulating therapy, of course, requires the 
thorough studies including clinical trials.   
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9 PERSPECTIVES 
 
To make the patient profiling more precise, it would be necessary to focus on (1) autoimmune 
phenomena with regards to auto-antibodies and idiotypic regulating networks, (2) the 
potential relationship between the pathophysiology of repeated IVF failure and high levels of 
IgG4 potentially linked to “short-life” IgE, (3) blocking antibodies towards IgA, IgM, IgE and 
the role of cross-reacting antibodies, (4) the immuno-modulatory effect of IVIg for treatment, 
and (5) better understanding of local immunity. 
Auto-antibodies are immunoglobulins naturally present in the human body and react with 
at least one self-antigen. The role of autoantibodies in immune regulation is not negligible. 
Potentially, they may act on the peripheral immuno-suppressive level. It is known that  
auto-antibodies are produced in IgM and IgA as well as the IgG isotype. The class switch 
causes µ-chains turning into -chains, which results in IgG predominance in the serum.  
As of yet, the detailed mechanism remains unclear. This type of antibody is characterized by 
low and broad affinity, high avidity and connectivity, being the first line defense against 
infection, clearance of aging cells, and anti-tumoral and anti-inflammatory control  
(Lacroix-Desmazes et al., 1998). All of these aspects are necessary to be considered in auto- 
as well as iso-immune reaction of women to male semen samples. The study of B- and T-cells 
in infertile women within the selected pathology would provide complex information 
concerning how to exert immuno-regulation evoked by IVIg. In addition, the characterization 
of the idiotypic network in infertile patients in comparison with fertile individuals would 
contribute to the research dealing with blocking antibodies towards IgA, IgM, IgE. Given that 
the anti-inflammatory and blocking potential of IgG4 (Aalberse and Schuurman, 2002;  
Guma and Firestein, 2012), it would be possible to specify its connectivity to IgE with respect 
to a local allergic reaction, later observed without obvious symptoms and complications. 
Cervical mucus samples subjected to more detailed analyses might be of potential interest to 
immuno-vaccines with regards to the presence of anti-seminal/sperm antibodies. 
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13 LIST OF ABBREVIATIONS  
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APC   antigen-presenting cells 
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AR   acrosome reaction 
ART   assisted reproductive technologies 
ASA   anti-sperm antibodies 
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CD   cluster of differentiation 
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D   derivates 
DAG   diacylglycerol 
DC   dendritic cells 
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ELISA   enzyme linked immuno sorbent assay 
FA   fatty acids 
FL   fusiogenic lipids 
FPP   fertilization promoting peptide 
FSH   follicle-stimulating hormone 
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NK cell  natural killer cell 
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PD   protein derivates 
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PKA   protein kinase A 
PLC   phospholipase C 
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PLA   phospholipase A 
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PTP   protein tyrosine phosphorylation 
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TGFȕ   transforming growth factor beta 
TGFȕI   transforming growth factor beta I 
Th   T helper cells 
THS   thyreotropin  
TKR   tyrosine kinase receptor 
TKR R2  tyrosine kinase receptor R2 
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T3   triiodothyronine  
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14.1.1 Tumor markers and their use in clinical practice 
 
Tumor markers are quoted as cancer or oncological markers as well. They are substances 
produced either by tumor or normal cells in a response to the development of cancer. Since 
their level in peripheral circulation is related to the severity of disease, these markers are used 
for the detection, diagnosis, prognosis, progression and control of treatment. Given that there 
is no absolutely specific or universal cancer marker, a set of different markers for different 
cancer types are used in clinical practice. A problematic feature of using these as diagnostic 
tools is their false positive results in both physiological as well as non-cancer conditions. 
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14.1.2 Indoor long-term persistence of cypress pollen allergenic potency: a 
10-month study 
 
Cypress pollen represents one of the primary causes of late winter respiratory allergies, rhino-
conjunctivitis and allergic asthma. Cypress pollen grains are very abundant during  
the pollinating season and are outdoor and/or indoor deposited where they may persist for  
a long time.  
In this study, indoor persistence related to the allergenic potency of Cupressus 
sempervirens pollen grains was evaluated with regards to time (2, 6, 8, 10 months), 
temperature, light and humidity variations found in a living home regardless of storage 
conditions. Using enzyme linked immuno sorbent assay (ELISA) and immunoblotting, we 
proved the persistence of the entire collection of allergens, detected in an unexposed fresh 
pollen extract. We demonstrated that there was no change in the in vitro allergenic potency of 
Cupressus sempervirens pollen grains after a 10-month exposure period to an indoor 
environment representative of a home exposure site. Based on our results, we concluded that 
cypress pollen allergens might have induced the lasting symptoms in the sensitized patients. 
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14.1.3 Complementarity between microarray and immunoblot for the 
comparative evaluation of IgE repertoire of French and Italian cypress 
pollen allergic patients 
 
Cypress pollen represents the primary cause of respiratory allergies in Mediterranean areas.  
In this paper, we compared 2 component-resolved explorative techniques in prior to specify 
the sensitization profiles of French and Italian patients suffering from a common cypress 
pollen allergy. Then, we described the IgE repertoires of French and Italian Cupressus 
sempervirens pollen allergies (CPA) probably related to the local environmental exposure. 
Patients allergic to Cupressus sempervirens pollen (Cups) can be discriminated on the basis of 
the IgE binding to a basic 14 kDa protein (BP14) or to high molecular weight (HMW) 
glycoproteins.  
Specific IgE repertoire of two differentially exposed CPA cohorts, French and Italian, were 
investigated using the IgE microarray system and the individual IgE immunoblotting (IB) of 
whole Cups pollen extract separated by SDS-PAGE. 
The prevalence of sensitization to BP14 was higher in French (37%) than in Italian patients 
(17%). Major differences were observed in IgE reactivities to Lipid Transfer Proteins (LTPs). 
Thirty percent of the Italian CPA (4% in the French group) had specific IgE against the 
Parietaria pollen LTP. Regarding peach LTP sensitization, all Pru p 3+ Italian CPA (10%) 
were in the HMW+ subgroup while Pru p 3+ French CPA (20%) were all included in the 
BP14+ subgroup. BP14 sensitization could be a marker of Cups exposure and is, in French 
CPA, significantly correlated to Pru p 3 sensitization. We proved that the IgE immunoblots 
and microarrays were efficient complementary tools to refine the sensitization profiles of 
French and Italian patients suffering from a common cypress allergy widely distributed 
around the Mediterranean basin. 
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Abstract. Cypress pollen represents the primary cause of respiratory allergies in 
Mediterranean areas. Patients allergic to Cupressus sempervirens pollen (Cups) (CPA) can be 
discriminated on the basis of the IgE binding to a basic 14 kDa protein (BP14) or to high 
molecular weight (HMW) glycoproteins only. Specific IgE repertoire of two differentially 
exposed CPA cohorts, French and Italian, were investigated using an IgE microarray system 
(some known major allergens from several allergenic sources) and individual IgE 
immunoblotting (IB) of whole Cups pollen extract separated by SDS-PAGE (all allergens 
from one allergenic source: cypress pollen). The prevalence of sensitization to BP14 was 
higher in French (37%) than in Italian patients (17%) and major differences were observed in 
IgE reactivities to Lipid Transfer Proteins (LTPs). Thirty percent of the Italian CPA (4% in 
the French group) had specific IgE against the Parietaria pollen LTP, independently of IB 
sub-groups. Regarding peach LTP sensitization, all Pru p 3+ Italian CPA (10%) were in the 
HMW+ subgroup while Pru p 3+ French CPA (20%) were all included in the BP14+ 
subgroup. BP14 sensitization is likely a marker of Cups exposure and is, in French CPA, 
significantly correlated to Pru p 3 sensitization. The IgE immunoblot and microarray are 
complementary tools that highlight differences in the subtle sensitization profile between 
groups of patients in comparative studies. 
 
Key words. Cupressus sempervirens; pollen allergens; immunoblot; allergen microarray; 
 
Introduction 
Cypress pollen is considered the primary cause of rhino-conjunctivitis and allergic asthma in 
areas surrounding the Mediterranean basin (Bountin-Forzano et al., 2005). The cypress, largo 
sensu belongs to the Cupressaceae family in which 4 species have been studied in detail 
concerning their high allergenicity: Cupressus arizonica (Cupa, Arizona cypress), Cupressus 
sempervirens (Cups, Italian cypress), Juniperus ashei (mountain cedar) and Cryptomeria 
japonica (Cryj, Japanese cedar) responsible for well-studied allergic disorders in Japan 
(Okamoto et al., 2009). A study, performed on 23,077 Italian allergic patients using the 
Immuno Solid-phase Allergen Chip (ISAC®) microarray technique, showed that, among 75 
allergens, Cup a 1 (the major allergen of Cupa), exhibited the highest prevalence of IgE 
sensitization (about 43%) (Scala et al., 2010). 
Proteins belonging to pectate lyase, polygalacturonase, thaumatin-like protein and Ca-binding 
protein families currently constitute groups 1 to 4 of cypress-cedar allergens, respectively 
(www.allergen.org or www.allergome.org). In Cups pollen, only 2 allergens are officially 
classified in the data bank of the International Union of Immunological Societies (IUIS). The 
pectate lyase Cup s 1, represents the major allergen and is highly cross reactive with Cup a 1 
and Cry j 1 (Arilla et al., 2004) whereas Cup s 3, identified using cDNA cloning and 
homology sequence analysis, seems to be absent or poorly expressed in Cups pollen grains 
(Togawa et al., 2006). Based on inhibition assays and specific IgE cross reactivity, Cups 
pollen extracts were also suspected to contain other allergenic components belonging to the 
profilin and ȕ-galactosidase protein families (Bistoni et al., 2005, Barderas et al., 2004).  
We have recently reported that the use of detergent, chaotropic agents or saline conditions can 
solubilize additional allergens from Cups pollen (Shahali et al., 2010). Furthermore, a 
proteomic analysis using combinatorial peptide ligand libraries as selective purification 
techniques of extracted pollen proteins lead to the description of 10 unreported allergens 
(Shahali et al., 2012a). In particular, we have identified with >65% coverage in protein 
sequence the polygalacturonase of Cupressus sempervirens (putative Cup s 2) (data not 
shown, Shahali et al., 2012b) and we showed that the IgE reactivity to a 14 kDa basic allergen 
(BP14) in Cups pollen extracts could discriminate between 2 types of cypress pollen allergic 
patients (CPA). A first set of patients displayed a heterogeneous IgE reactivity to high 
140 
 
molecular weight (HMW, >30kDa) allergenic glycoproteins while specific IgE of a second set 
of patients mainly bound to BP14 (Shahali et al., 2012c).  
The diagnosis of type 1 hypersensitivity is mainly based upon an evocative anamnesis and 
clinical history and in vivo skin prick tests. Then, in vitro  detection of specific IgE against 
sensitizing molecular allergens can be performed using either commercial procedures in 
single or multi array (Mari et al., 2010)  or immunoprint after separation of proteins from raw 
extract by electrophoresis in 1 or 2-dimensions (Le Mao et al., 1998, Poncet et al., 2010). 
The aim of this study was to compare the IgE repertoire of CPA from France and Italy using, 
on one side, immunoblots with a Cups pollen extract and, on the other side, IgE microarray 
assay. Total IgE content as well as the specific reactivity towards a commercial Cups extract 
in classical immunoCAP (t23) assay were also evaluated. Results showed that the 2 analytical 
methods are complementary and suggest that co-sensitization and/or cross-reactivity and 
exposure play a role in shaping the subtle IgE repertoire in cypress pollen allergic patients. 
 
Methods 
Patient sera 
This study has been approved by the institutional ethical committees (approval numbers: 
2011-A00211-40 and 106-CE-2005) and written informed consent has been obtained from 
patients. Fifty-one CPA from Marseille, France, and 30 CPA from Rome, Italy, were selected 
according to their clinical symptoms (rhinitis, conjunctivitis and asthma) during cypress 
pollinating season. Mean age of French cohort was 40.3 years (range, 10-74) in a group of 28 
females and 23 males and mean age of Italian cohort was 32.7 years (range, 11-62) in a group 
of 16 females and 14 males. For each immunoblot analysis, the serum from a healthy 
individual was used as a negative control. 
 
Cypress pollen protein extractions  
Cups pollen was supplied by Allergon AB (Angelholm, Sweden). One hundred mg of pollen 
was incubated for 18 h in a buffer containing 4% SDS. The pollen suspension was then 
centrifuged at 18,000 g for 20 min at 4°C, as previously described (Shahali et al., 2010). The 
supernatant was collected and stored as aliquots at -20 °C until use. The protein concentration 
in supernatants was measured with Bradford protein assay (Pierce, Thermo Scientific, 
Rockford, USA) on samples diluted to reduce the concentration of SDS <0.1% according to 
the manufacturers‟ recommendations in order to prevent interferences. Bovine serum albumin, 
used for protein calibration curve, was diluted in 0.1% SDS solution. 
 
One-dimensional gel electrophoresis  
For 1-DE SDS-PAGE separation, extracted proteins in a 38 mmol.l-1 Tris buffer pH 6.8 
containing 4% (w/v) SDS were applied to a thin 8-18% gradient polyacrylamide gel 
(ExcelGel, GE Healthcare, Uppsala, Sweden) and run on a flat-bed electrophoretic chamber 
(Multiphor II, GE Healthcare) at 12 °C. The gel was then either transferred onto a cyanogen 
bromide activated nitrocellulose (NCa, Demeulemester et al., 1987) sheet (Optitran®BA-S 83, 
Schleicher and Schuell, Dassel, Germany) for western blotting assays or stained for detection 
of the separated proteins. Molecular mass (Mr) markers (GE Healthcare) ranging from 14.4 to 
94 kDa were used as comparative references.  
 
Immunoblotting 
Electroblotting of separated proteins was performed onto NCa sheets with a semidry Novablot 
apparatus (LKB, Uppsala, Sweden) following the manufacturer‟s instructions (1 h, 1 mA/cm2). 
The membranes were then dried and blocked with PBS containing 0.3% (v/v) Tween 20 
(Sigma-Aldrich) (PBS-Tw) for 1 h at 20 °C. For 1-DE screening, each NCa was then cut in 
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2.5 mm wide strips that were individually incubated with 1:10 diluted patient or control sera 
in PBS-Tw 0.1% (overnight at 20 °C). Each membrane was washed 3 times for 10 min in 
PBS-Tw 0.1 % (v/v) and incubated during 2 h at 20 °C with 1:700 dilution of alkaline 
phosphatase (AP)-conjugated goat anti-human IgE (Sigma-Aldrich). The AP activity was 
detected using 5-bromo-4-chloro-3-indolyl phosphate (BCIP, Sigma) and nitro blue 
tetrazolium (NBT, Sigma) in 0.1 mol.l -1 Tris acetate buffer pH 9.5. 
 
Total and specific IgE evaluation 
Total IgE levels were assayed by nephelemetry (BNII, Siemens) and expressed in IU.ml-1. 
Specific IgE to cypress allergen (Cupressus sempervirens, reference code t23) were quantified 
with the widely used fluorescence enzyme immunoassay (FEIA) ImmunoCAP® 
(ThermoFischer Scientific) on the ImmunoCAP 250 apparatus, as recommended by the 
manufacturer. The detection limit was 0.10 kU.l-1. Specific IgE evaluation was performed on 
46 French and on 30 Italian CPA using the commercial allergen microarray ImmunoCAP 
ISAC® 10γ according to the manufacturer‟s instructions. The raw data were expressed as 
ISAC standardized units (ISU) and levels above 0.1 ISU were considered positive. 
 
Statistical analysis 
The differences in variables were evaluated using the analysis of variance (ANOVA) and 
Fisher‟s exact test. 
 
Results 
Immunoblot: IgE sensitization to BP14 is lower in prevalence in Italian patients 
Sera from French (n=51) and Italian (n=30) patients were screened by 1-D immunoblots using 
SDS Cups pollen extract. In agreement with our previous results, 3 IgE reactivity patterns 
were observed. IgE from some patient sera bound BP14 with or without reactivity to HMW 
allergens (19 in French patients, i.e. 37% and 5 in Italian patients, i.e. 17%, see lines 
“Immunoblot” in table 1). IgE from other patient sera only bound to HMW and not to BP14 
(41% and 60% of French and Italian CPA, respectively), and a third category was negative for 
all proteins of the extract (22% of the French patients and 23% of the Italian cohort). The 
results of 3 representative sera for BP14 and HMW sub-groups and one for the negative 
subgroup are depicted in Fig. 1 for French and Italian patients (Fig. 1A and 1B, respectively). 
These 3 groups will be referred as immunoblot (IB) sub-groups, BP14+, HMW+ and Neg in 
the rest of the study. 
 
Microarray: a minority of cypress allergic patients are monosensitized 
IgE immunoreactivity results are separately represented in Fig. 2 for French patients and in 
Fig. 3 for Italian patients. Demographic and clinical characteristics are given on the left sides 
of Fig. 2 and 3 (the correspondence letter code for molecular allergens and extracts are 
presented in table 2) and specific global percent reactivity to cypress allergens are shown in 
table 1. Most of the patients exhibited rhinoconjunctivitis, in both cohorts and, independently 
of the IB sub-groups, asthma was also observed in 35% of French and 10% of Italian CPA. 
With regards to microarray results (right side of both Fig. 2 and 3), the proportion of 
monosensitized versus polysensitized CPA was quite low both in French (13%) and Italian 
(10%) patients. The proportion of pollen-polysensitized patients was similar in French and 
Italian cohorts, 17% versus 20%, respectively. In contrast, the proportion of Italian patients 
allergic to multi-categories of allergens (i.e. all pollen plus other allergens) was high (63%) 
while it only reached 46% in French patients. Patients with a pollen sensitization limited to 
cypress along with a sensitization to non-pollen allergens represented 15% for French and 7% 
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for Italian CPA. These mono, pauci and polysensitizations seem to be independent of the 3 IB 
sub-groups. 
Individual levels of specific IgE reactivity to Cup a 1, Cry j 1 and Cups as well as total IgE 
are graphically shown in Fig. 4 for each IB subgroup. Specific IgE to Cups (t23), Cup a 1 and 
Cry j 1 values were significantly higher in Italian patient group than in French one 
independently of IB subgroups (p<0.05) and total IgE levels showed a tendency to be lower in 
French than in Italian CPA patients (p=0.1019) (Fig. 4). While similar values of Cup a 1 and 
Cry j 1 specific IgE were observed in the Italian cohort (mean 18.6 and 20.4 ISU respectively), 
they were significantly lower for Cry j 1 than for Cup a 1 in the French patients independently 
of IB subgroups (mean 3.4 and 7.1 ISU respectively, p=0.0129). Interestingly, Cups (t23) 
specific IgE were significantly higher (p<0.05) in the BP14 sub-group as compared with 
HMW and Neg sub-groups in the French patients. 
 
LTPs are the discriminating allergens 
Data of Fig. 2 and 3 were also globally interpreted as histograms in Fig. 5 pointing out the 
percentages of positive sera for allergens or groups of allergens in order to compare French 
and Italian repertoires. The overall qualitative diversity was similar and 4 allergen sources 
showed quantitative differences. Grass pollen (35% vs. 80%), PR10 (2% vs. 17%), profilin (4% 
vs. 17%) and house dust mite (17% vs. 37%) sensitizations were higher in Italian than in 
French CPA. However, the most striking qualitative and quantitative difference was found for 
LTP sensitization. Italian CPA were significantly more sensitized to Parietaria pollen LTP as 
compared to French CPA (30% versus 4%, respectively, p= 0.004) whereas sensitization to 
peach LTP reached 20% in the French and 10% in the Italian CPA. This outcome prompted 
us to assess how these reactivities were distributed among each IB sub-group. While the 
reactivity of CPA to the main type of allergens - pollen, animals and house dust mites - was 
equally distributed among the 3 IB sub-groups, both in French and Italian patients (data not 
shown), the reactivity to peach LTP was strictly restricted to BP14 IB sub-group in French 
CPA. The 9 Pru p γ+ French patients were all included in BP14+ patient‟s sub-group while 
the 3 Pru p 3+ Italian patients were in the HMW+ sub-group (Fig. 6). This correlation is 
statistically significant (p=0.01) and is consistent with the anamnetic investigation revealing a 
higher proportion of fruit allergy in BP14+ French patients subgroup than in HMW+ 
subgroup (left side of Fig. 2). Interestingly, no preferential association was found for the 
reactivity to Parietaria pollen LTP Par j 2 in Italian patients since it was found in the 3 IB 
sub-groups (Fig. 6). 
 
Discussion 
Aside from the clinical symptoms collected by a physician in a traditional anamnesis, 
diagnosis is usually established with skin prick test and biological test evaluating the presence 
of specific IgE against a panel of allergens.  
An optimized total extract has the advantage of containing the whole collection of 
components to which the individual has been exposed and is thus crucial to decipher the 
complete repertoire of a patient‟s IgE against a given source. Electrophoresis constitutes a 
useful tool to separate proteins from an allergenic extract and double dimension gel 
electrophoresis offers the best resolution (Poncet et al., 2010, Shahali et al., 2008, Le Mao et 
al., 1998). Coupled to immunoblotting with patient‟s IgE and mass spectrometry of 
recognized allergens, this immunoproteomic approach evaluate the diversity of sensitizing 
allergens as well as the diversity of the individual IgE immune response. However, since the 
technique is not yet miniaturized, it is tedious, time- and reagent-consuming when several 
allergenic sources have to be studied. 
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In contrast, a multiplexed microarray device, used for in vitro diagnosis, consumes low 
amount of serum, can be automated and delivers the results of IgE binding on more than 100 
molecular native or recombinant allergens covering representative group markers of plant and 
non-plant allergenic sources (Mari et al., 2010). A large repertoire of allergen reactivities can 
thus be explored in selected physio-pathological models on already known and well 
characterized molecular allergens. One obvious drawback is, of course, the inability to 
evaluate reactivity to a molecular allergen that has not been previously reported. Non-
hydrosoluble allergens, for example, represent one such class that remains poorly-studied 
until now (Godfrin et al., 2007). 
Consequently, for purposes of research, these 2 techniques can be considered as 
complementary since immunoblots yield the complete allergen repertoire from a given 
allergenic source and the microarray gives a global reactivity overview against several 
allergenic sources. 
We combined these 2 technologies to the study of cypress pollen allergy, a pervasive 
pollinosis in areas surrounding the Mediterranean basin. Very few studies are available on the 
IgE repertoire of cypress allergic French patients (Caimmi et al., 2013, Boutin-Forzano et al., 
2005) whereas this pollinosis is more documented in Italy and Spain (Tordesillas et al., 2011, 
Papa et al., 2001, Corsico et al., 2000). We previously reported that CPA can be classified in 
2 groups according to IgE immunoblot patterns after migration of a cypress extract in 1-D and 
2-D gel electrophoresis: CPA with anti-HMW allergen reactivities and those expressing IgE 
against BP14, a basic protein of 14 kDa (Shahali et al., 2012b, Shahali et al., 2012c, Shahali et 
al., 2010). Proteomic analysis of cypress pollen extract in two-dimensional gel electrophoresis 
(2-DE) showed that the only protein found at 14 kDa in a PBS cypress extract is the cationic 
BP14 (Shahali et al., 2012b, Shahali et al., 2012c) making of the immunoblot after 1-DE a 
valuable and reliable method to assess CPA profile. 
The comparison of the IgE immunoblot patterns of 2 cohorts of CPA, one from Rome, Italy 
and the other one from Marseille, France, showed that the anti-BP14 specificity was less 
represented in Italian patients. Together with microarray evaluation of sensitization patterns 
and the determination of Cup a 1, Cry j 1 and Cups specific IgE levels, our results point out 
some differences that might be attributed to variable exposure to local trees and/or other 
allergenic environments. Indeed, as compared to the Arizona cypress (Cupressus arizonica) 
and Japanese cedar (Cryptomeria japonica), the Italian cypress (Cupressus sempervirens) 
pollen is richer in BP14 (Shahali et al., 2012c) (with or without SDS in extraction buffer -
unpublished data-) and is the most abundant species in the south of France, where it 
represents more than 80% of Cupressaceae. Conversely, the Arizona cypress is predominant 
in urban and peri-urban areas in Italy (Christian Pichot, INRA, France, personal 
communication). This might be one of the main reason explaining why patients allergic to 
cypress pollen and showing anti-BP14 IgE, are more frequent in the south of France. 
Microarray experiments also revealed some differences in sensitization to LTPs. Thirty 
percent of Italian CPA reacted to Parietaria pollen LTP (Par j 2), independently of IB sub-
groups and 20% of French patients reacted to peach LTP (Pru p 3) with a strong correlation 
with the BP14 sub-group. This correlation was not observed for the 3 Italian patients 
sensitized to Pru p 3 that fall in the HMW sub-group. LTPs constitute a group of 
heterogeneous allergens where no IgE cross-reactivities are found between Parietaria pollen 
and food LTP including peach (Tordesillas et al., 2011, Egger et al., 2010). We confirm these 
results since no co-sensitization Pru p 3/Par j 2 was observed, neither in French nor Italian 
CPA. This result is also in agreement with the absence of detected cross reactivity between 
cypress pollen allergens and plant-derived food in cypress pollen monosensitized Italian 
patients (Panzani et al., 2010). A relationship between cypress pollen and peach allergy has 
already been reported (Delimi et al., 2007, Hugues et al., 2006), in which the authors 
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suggested, upon immunoblot inhibition experiments, that proteins around 45 kDa might be the 
cross-reactive allergen (Hugues et al., 2006). The fact that Pru p 3 reactive CPA were found 
in the BP14 sub-group (in French patients only) was unexpected and raised the question of the 
nature of BP14. LTPs are small in molecular masses (6-14 kDa) and basic in terms of 
isoelectric point values. These characteristics are shared with BP14 and several experiments 
were performed to unravel the physico-chemical nature of BP14. These experiments included 
chromatographic methods specifically adapted to purify LTPs, immunoblots using specific 
anti-Pru p 3 rabbit antibodies and more than 25 trials of characterization by mass 
spectrometry analysis. The analysis of accumulated data led to the conclusion that there is no 
obvious direct immunochemical and structural relationships between known LTPs and BP14. 
Homology searches using a sequence of 9 N-terminal amino-acids of BP14 (unpublished data) 
confirmed that this protein is currently absent from data banks and displays no identical 
characteristics with the Cupressaceae pollen LTP described as an allergen in Japanese cedar 
(Ibrahim et al., 2010). A LTP has also been immunochemically described in Cupressus 
arizonica pollen (Sanchez-Lopez et al., 2011). Efforts are still ongoing in our group to 
structurally characterize BP14 whose IgE response seems to be a specific marker of 
sensitization to Cups pollen (Shahali et al., 2012b) and is associated with a Pru p 3 
sensitization in French CPA only.  
In conclusion, by combining 2 component-resolved explorative techniques, we highlighted 
some of the differences shaping the IgE repertoires of French and Italian CPA. These 
differences are related to the allergenic biodiversity of the local environmental exposure, 
either the species of cypress, arizonica versus sempervirens or the co-sensitization source, 
peach or Parietaria LTP. Using immunoblot, the IgE reactivity against numerous allergens in 
one allergenic source was revealed, and using microarray, some representative allergens of 
several allergenic sources were studied. These approaches have proven to be complementary 
and were used herein to efficiently decipher and refine sensitization profiles of French and 
Italian patients suffering from a common cypress allergy widely distributed around the 
Mediterranean basin. 
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Figures 
 Fig. 1: Three immunoblot patterns obtained with representative patients‟ sera. An SDS protein extract of 
Cupressus sempervirens pollen separated in SDS-PAGE were blotted onto an NCa membrane. Each strip was 
individually incubated with sera from French (n=51) and Italian (n=30) CPA. Three representative patterns for 
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BP14 and HMW and one for negative (Neg) sera are shown for French (A) and Italian (B) CPA. Percentages in 
each sub-group and molecular mass (kDa) are indicated. 
 
 
 
Fig. 2: Clinical and biological data of 46 French CPA. a: symptoms included R: rhinitis, C: conjunctivitis and A: 
Asthma. b: SPT: Skin Prick Test with standardized extracts. QO: Quincke oedema. c: results of IgE immunoblot 
are semi quantitatively expressed according to the intensity of the reaction. -: negative; +/-: low, +: medium; ++: 
high, +++: very high. Letter code for allergens or groups of allergens is similar for SPT and microarray results 
(see table 2). Close circle: positivity (ISU > 0.3). Open circle: low positivity (0.1<ISU<0.3). --- : negative (ISU < 
0.1). 
 
 
Fig. 3: Clinical and biological data of 30 Italian CPA. a: symptoms included R: rhinitis, C: conjunctivitis and A: 
Asthma. b: SPT: Skin Prick Test with standardized extracts. c: results of IgE immunoblot are semi quantitatively 
expressed according to the intensity of the reaction. -: negative; +/-: low, +: medium; ++: high, +++: very high. 
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The correspondence of letter code with molecular allergens for microarray is given in table 2. Close circle: 
positivity (ISU > 0.3). Open circle: low positivity (0.1<ISU<0.3). --- : negative (ISU < 0.1). 
 
 
Fig. 4: Individual distribution plots of specific (A and B) and total IgE (C) levels in French and Italian CPA and 
for each IB sub-group. (14) open circles: BP14 sub-group, (H) close triangles: HMW subgroup, (N) open 
diamond: Neg sub-group. Horizontal bars in each sub-group represent the mean value. Total IgE was quantified 
by nephelemetry and expressed in IU.ml-1. ImmunoCAP specific IgE levels to the whole Cups pollen extract 
(t23) were indicated in IU.ml-1. The level of specific IgE to nCup a 1 and nCry j 1 was determined with 
ImmunoCAP ISAC and expressed in ISU.  
 
 
Fig. 5: Comparative distribution of IgE reactivities in French and Italian CPA patients. Data from the 
commercially available microchip array ISAC® (103 allergens) are presented as percentages of positive sera for 
each allergen or group of allergens. See table 2 for letter code correspondence. White histograms: French CPA, 
black histograms: Italian CPA. Pollen allergenic sources, LTP and animal-derived allergens are grouped in boxes 
to facilitate the comparisons. 
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Fig. 6: Distribution of LTP sensitization obtained by microarray ISAC® (103 allergens) within IB subgroups in 
French and Italian patients. Each subgroup, HMW, BP14 and Neg, is indicated with the number of patient.   : 
patient sensitized to peach LTP (Pru p 3), : patient sensitized to mugwort LTP (Art v 3) and   : patient 
sensitized to Parietaria LTP (Par j 2). 
 
Table 1: IgE reactivity of French and Italian cohorts to allergens or specific extract from Cupressus sempervirens 
using different techniques 
 
Technique Cypress allergen or 
extract 
Frencha Italiana 
Microarray Cup a 1 91 100 
Microarray Cry j 1 85 100 
FEIAb Cup s (t23) 89 100 
Immunoblot Cup s HMW 41 60 
Immunoblot Cup s BP14 37 17 
a Results are expressed in % positive patient serum. 
b Fluorescence Enzyme Immuno Assay 
 
Table 2: Correspondence letter code for molecular allergens and extracts used for figure 2 and 3. For SPT 
reported in figure 2 letter code represents total extract source. 
 
            
  code source species Molecular Allergen 
plant food K Kiwi  
 
nAct d 2 
  
 
S Soybean 
 
nGly m 5, 6 
 
 
W Wheat   nTri a 18 nTri a gliadin 
Pollen G Grass pollen Bermuda  nCyn d 1 
  
   
Timothy rPhl p 1, 2, 5 , 6, 11 nPhl p 4 
 
O Olive pollen 
 
nOle e 1 
  
 
L Plane pollen 
 
rPla a 1 nPla a 2 
 
 
Cy Cypress pollen Arizona cypress Cup a 1 
  
   
Japanese cedar Cry j 1 
  
 
B Ragweed pollen 
 
nAmb a 1 
  
 
V Mugwort pollen 
 
nArt v 1 
  
  S Saltwort pollen   nSal k 1     
  H Latex   rHev b 5, 6     
 
PR10 PR10 family Birch pollen rBet v 1 
  
   
Alder pollen  rAln g 1 
  
   
Hazel pollen rCor a 1.11 
 
   
Hazelnut rCor a 1.41 
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Apple rMal d 1 
  
   
Peach rPru p 1 
  
   
Soybean rGly m 4 
  
 
    Peanut rAra h 8     
LTP family J Peach 
 
nPru p 3 
  
 
V Mugwort 
 
nArt v 3 
  
  P Wall Pelitory  (Parietaria) rPar j 2     
Profilin 
family Prof Profilins Birch rBet v 2 
  
   
Olive nOle e 2 
  
   
Latex rHev b 8 
  
   
Mercury rMer a 1 
  
      Timothy rPhl p 12     
 
CBP Ca binding  Birch rBet v 4 
  
    protein Timothy rPhl p 7     
 
E Egg 
 
nGal d 3 (ovotransferrin) 
 
M Milk 
 
nBos d lactoferrin 
 
  Co Cockroach   rBla g 5     
 
C Cat 
 
rFel d 1, 4 
  
 
F Dog 
 
rCan f 1, 2 
  
  Mo Mouse   nMus m 1     
Mold T Alternaria 
 
rAlt a 1, 6 
  
  A Aspergilus   rAsp f 4     
 
D House Dust  D. pteronyssinus nDer p 1, 2 
  
     Mite D. farinae nDer f 1, 2     
 
Parva Parvalbumin Carp rCyp c 1 
  
      Cod rGad c 1     
 
Tropo Tropomyosin Shrimp rPen a 1 nPen i 1 nPen m 1 
   
Mite rDer p 1 
  
   
Cockroach Bla g 7 
  
      Anisakis rAni s 3     
 
Alb Animal serum  Cow  nBos d 6 
  
  
albumin Cat nFel d 2 
  
   
Dog nCan f 3  
  
      Horse nEqu c 3     
        
 
 
